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CHAPTER l 
HYPERPROLACTINEMIA IN MAN 
I. Introduction 
The importance of prolactin (PRL) as a regulator 
of reproductive functions in mammals and birds was 
established within a few years of its discovery in 
1928 (Stricker & Grueter, 1928). Since the isolation 
and specific radioirnrnunological determination of 
human PRL (Guyda et al., 1971; HWang et al., 1971), 
PRL has become a hormone of considerable clinical in-
terest especially in the diagnosis and management of 
pituitary tumors. However, up to now little is known 
about the physiologic role of PRL in man. The prin-
cipal action of PRL in mammals in general is stimula-
tion of milk formation in the hormonally prepared fe-
male breast (Ganong, 1980). Furthermore hyperprolac-
tinernia, whether due to hypothalamic-pituitary dis-
orders, drug use, hypothyroidism or other diseases, 
is associated with reproductive dysfunctions in men 
and women (see review von Werder et al., 1977; Kirby 
et al., 1979). The association of hyperprolactinemia 
with galactorrhea and menstrual irregularities has 
been recognized for many years (Jacobs et al., 1976). 
Hyperprolactinemia in male patients does not cause 
"typical .. manifestations and may not be recognized by 
the patient or his physician (Carteret al., 1978). 
Impotence, loss of libido, hypogonadism, impaired 
spermatogenesis, gynecomastia and galactorrhea can be 
observed (see review Hermanns & Hafez, 1981). Hyper-
11 
prolactinemia can be detected in male patients with 
infertility, impotence and hypogonadism. 
The mechanisms by which hyperprolactinemia lead to 
reproductive dysfunctions have not yet been esta-
blished. Stimulatory as well as inhibitory effects 
of increased PRL levels on reproductive functions 
have been described, as will be apparent from the 
next paragraphs. Several hypotheses have been pro-
posed to account for these dysfunctions in hyperpro-
lactinemic males: 
a. Interference by PRL at the hypothalamic and/or 
pituitary level. 
b. Interference at the peripheral level: 
- Blockade of the effects of gonadotropins at the 
gonadal level. 
- Functional impairment of the accessory sex 
glands indicating a possible interaction between 
PRL and testosterone. 
- Direct impairment of sperm motility and/or other 
sperm qualities. 
c. Alterations in adrenal steroidogenesis. 
In order to elucidate the mechanisms involved in 
the relationship between PRL and reproductive func-
tions, we have collected information on four groups 
of male patients: 
1. Men with hyperprolactinernia caused 
ting pituitary adenomas (paragraph: 
by PRL-secre-
2) • 
2. Healthy volunteers in whom hyperprolactinemia was 
induced by neuroleptics and other drugs 
(paragraph: 3.1). 
3. Men with other diseases associated with hyperpro-
lactinemia (paragraph: 3. 2) . 
4. Men with infertility and/or impotence 
4) . 
12 
(paragraph: 
Relevant information about these groups of pati-
ents as reported in the literature will be discussed 
in the next paragraphs. 
2. PRL-secreting pituitary adenomas 
In 1972 a case of a 24 yr-old male with idiopathic 
galactorrhea and mild hypogonadism has been reported 
(Volpe et al., 1972). This patient presented with 
gynecomastia and galactorrhea. Libido and penile 
erections were normal. He had mild hypogonadism, 
manifested by low plasma testosterone levels and oli-
gozoospermia. A testicular biopsy showed histologi-
cally moderate gonadal atrophy. Basal serum gonado-
tropin levels were normal, while serum PRL levels 
were elevated. An explanation for the increased PRL 
levels could not be found; X-rays of the skull and 
pneumencephalography were normal. HOwever, the find-
ings in this patient could fit with the presence of a 
PRL-secreting microadenoma of the pituitary (tumor 
less than 1 em in diameter, sella described as not 
enlarged). 
Costello (1936) showed small pituitary adenomas in 
225 of 1000 routine autopsies. In a recent study 
(Burrow et al., 1981), microadenomas were found in 32 
of the 120 pituitaries removed at autopsy. 
percent of these microadenomas stained 
Forty-one 
for PRL. 
Twenty-seven of the 120 subjects had tomographic ab-
normalities compatible with the presence of a microa-
denoma. In 26 of 93 patients with a negative tomo-
graphy, a microadenoma was found. 
It is not surprising that prolactinomas are the 
most frequently diagnosed pituitary tumors both in 
men and women (Frantz, 1978). In contrast to the 
13 
many reports of prolactinomas in women, PRL-secreting 
adenomas in men have been much less extensively stu-
died (Grisoli et al., 1980). Several of these re-
ports on men with hyperprolactinemia and radiologi-
cally abnormal sellas are summarized in Table 1.1. 
In cases of a normal sella turcica the diagnosis pro-
lactinoma was made by excluding other causes of hy-
perprolactinemia. 
Differentiation between functional and tumorous 
hyperprolactinemia has to be achieved by several dia-
gnostic procedures: repeated PRL determinations, dy-
namic tests, polytomography of the sella, computer-
ized axial tomography (CAT), visual fields etc. 
2.1. Symptoms and signs 
In contrast to the findings in the above mentioned 
patient of Volpe, disturbances of potency and libido 
are prominent features in the majority of men with a 
PRL-secreting pituitary adenoma. Gynecomastia and 
galactorrhea have been less frequently described in 
men with prolactinomas (Table 1.1). Franks et al. 
(1976) suggested that in untreated patients with the 
combination of acromegaly and hyperprolactinemia im-
potence might be caused by PRL. Four of their 5 hy-
perprolactinemic men complained of loss of potency 
and libido. No improvement of these complaints was 
seen after operation in 2 of them, whose PRL levels 
were still high, while growth hormone (GH) levels 
normalized. Some patients recognized a decreasing 
volume of their seminal ejaculate (Thorner et al., 
1977). 
14 
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The testes may be of normal or small size and are 
usually soft. .In some patients the prostate is 
small. 
Surprisingly enough, relative few patients with 
impotence and loss of libido seek medical advice. 
The presenting clinical signs comprised headache, vi-
sual field defects or signs of hypopituitarism, 
caused by intra-, supra- and para-sellar extension of 
tumor mass. Retrospectively, sexual disturbances ap-
peared to have existed for a long time. 
2.2. Gonadotropins 
In 1974 basal serum gonadotropins and their res-
ponses to luteinizing hormone-releasing hormone (LRH) 
in 4 hyperprolactinemic men were presented by Thorner 
et al.. Both basal and stimulated values of LH and 
FSH turned out to be normal. The results of other 
studies are listed in Table 1.2. 
From these observations it can be learned that basal 
gonadotropin levels in untreated hyperprolactinernic 
men are mostly normal with a normal or decreased rise 
after administration of LRH. 
Recently Eversmann et al. (1981) showed an im-
paired response of LH and FSH to LRH stimulation in 
86% of 57 hyperprolactinemic men. In this study 49 
patients 
tuitary 
had a macroadenoma of whom 24 underwent pi-
surgery before the start of the study. 
Normal responses of serum gonadotropins to LRH have 
also been reported in men with macroadenomas (Table 
1.2). An exaggerated response of gonadotropins to 
LRH as described in hyperprolactinemic women and 
especially in women with microadenomas (Asfour, 1977; 
Thorner & Besser~ 1978; Monroe et al., 1981), is not 
a common finding in men. 
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Boyar et al. (1974) and Bohnet et al. (1975) stu-
died episodic LH secretion in hyperprolactinemic pa-
tients. Boyar et al. (1974), having studied 7 women 
and 2 men, found normal mean serum LH levels over 24 
hours and normal episodic fluctuations of LH concen-
trations in those hyperprolactinemic patients with a 
normal sella turcica and presumably a microadenorna. 
LH concentrations were low and episodic LH peaks ab-
sent in patients with radiologically obvious pituita-
ry tumors (macroadenomas). In the experience of Boh-
net et al. (1975) episodic LH peaks were absent in 12 
of 14 hyperprolactinernic women. 
In many hyperprolactinemic male patients testes-
terone levels have been reported to be low. The ob-
servations of "normal" basal gonadotropin levels to-
gether with normal or even exaggerated responses of 
gonadotropins to LRH in patients with prolactinomas 
suggest that the ability of the pituitary to secrete 
LH and FSH is intact. 
It has been postulated that PRL might inhibit endoge-
nous LRH release, although in human studies changes 
in LRH secretion can only be inferred from the study 
of peripheral gonadotropin levels. 
A relationship between low gonadotropin levels and 
elevated PRL secretion was originally proposed by Ben 
David et al. (1971) in rats. Hyperprolactinemia in 
rats resulted in an increased hypothalamic dopamine 
turnover rate, associated with decreased LH secretion 
(Hokfelt & Fuxe, 1972). If extrapolation of these 
data to men is justified, dopamine might also be in-
volved in gonadotropin secretion in hyperprolactine-
mic patients. In normal men and women dopamine-indu-
ced inhibition of LH secretion could be demonstrated, 
as shown by a reduction in both pulse 
amplitude of LH secretion (Leblanc 
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frequency and 
et al., 1976, 
Huseman et al., 1980; Ropert et al., 1981). 
Lache lin et al. ( 1977) reported a significant fall in 
LH and FSH levels following the administration of a 
single dose of bromocriptine (2.5 mg orally) to 6 
women with hyperprolactinemia. However, according to 
Thorner et al. (l980b) the same dose of bromocriptine 
given to 12 hyperprolactinemic women resulted in sup-
pression of PRL levels, without any effect on LH se-
cretiono The latter finding shows that bromocriptine 
obviously had no effect on serum gonadotropins. 
There are experimental data in healthy volunteers 
of both sexes which suggest that opioids might be in-
volved in regulating LH release (Grossman et al., 
1981). Recently, the suppression of serum LH levels 
in women with PRL-secreting rnicroadenomas have been 
explained by an increase of endogenous opioids 
(Lightman et al., 1980; Quigley et al., 1980; 
Lamberts et al. , 1981; Li ghtman et al., 1981) . 
Intravenous infusion or bolus injections of naloxone 
resulted in a rise of plasma LH in these hyperprolac-
tinemic women. 
It remains difficult to find a relationship 
between PRL and serum gonadotropin levels in hyper-
prolactinemic men, since most of the data are related 
to the presence of macroadenomas. In those situa-
tions destruction or local compression of normal pi-
tuitary tissue can be postulated. In hyperprolacti-
nernic women, however, there are some indications that 
elevated PRL levels can disturb serum gonadotropins 
by alterations of hypothalamic dopamine release, by 
suppression of the pulsatile LRH secretion, and by an 
increase in endogenous opioids. 
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2.3. Testicular functions 
2.3.1. Testosterone production 
From data on blood testosterone concentration 
under physiological and experimental conditions it 
appears that PRL may stimulate testicular steroido-
genesis in men. The sleep related increase of plasma 
testosterone in adult men is partially due to incre-
ased PRL levels (Rubin et al., 1975, 1976). Men with 
prolactinomas have low concentrations of plasma tes-
tosterone (Eversmann et al., 1981), which may in some 
patients be secondary to local destruction and/or 
compression of normal pituitary tissue, caused by a 
macroadenoma and resulting in LH deficiency. Never-
theless, low testosterone levels have recently also 
been reported in men with microadenomas (Spark et 
al., 1982). 
Changes in plasma testosterone levels after human 
chorionic gonadotropin (hCG) administration to hyper-
prolactinemic men have been found to be normal (Car-
teret al., 1978; Turpin et al., 1979b; Luboshitzky 
et al., 1979), but not in others (Fonzo et al., 1977; 
Thorner et al., 1977; Pei1lon et al., 1979). The 
cases, where blood levels of LH and FSH in hyperpro-
lactinemic men are normal, the elevated PRL levels 
may interfere with the action of gonadotropins on the 
gonads (Besser & Thorner, 1975). Further, hyperpro-
lactinernic hypogonadism could be due to the interfer-
ence of increased PRL with conversion of testosterone 
into biologically active dihydrotestosterone (DHT) 
which mainly occurs in peripheral tissues (Ito & Hor-
ton, 1971). Data in support of this view have been 
published by Lackritz & Bartke (1980). However, Tur-
pin et al. (l979b) were not able to show such an ab-
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normality in hyperprolactinemic men. 
2 3.2. Spermatogenesis 
Contradictory results have been reported with res-
pect to the literature of PRL on spermatogenesis. 
Elevated PRL levels have been found in patients with 
azoospermia (Suominen et al., 1979), oligozoospermia 
(Volpe et al., 1972; Luboshitzky et al., 1979), nor-
mozoospermia (Carter et al, 1978) and even polyzoos-
permia (Peillon et al., 1979; Snyder et al., 1979). 
Infertility was present in 10 out of a group of 25 
patients with prolactinomas (Peillon et al., 1979). 
Testicular biopsies may show testicular atrophy 
(Volpe et al., 1972) or normal spermatogenesis (Je-
quier et al., 1979). Infertility, however, may not 
only be due to hyperprolactinemia but also to hypogo-
nadism or impotence accompanying hyperprolactinemia. 
An example of such a possibility was published by 
Franks et al. (1978), who reported a hyperprolacti-
nemic patient with hypogonadism and infe.rtility, who 
was treated with hCG. Although the sperm counts were 
less than one million per ml, he fathered a child. 
Another interesting observation on a man with a 
PRL-secreting pituitary tumor was made by Baccetti et 
al. (1979), who reported bicellular spermatozoa, 
which disappeared after correction of the PRL levels, 
suggesting an effect of PRL on spermatogenesis. The 
patient had 3 children, the youngest was seven years 
old at the time of diagnosis. After PRL level redu-
cing therapy another son was born. Another patient 
with infertility and impotence was described by Hsu 
et al. (1978). Previously he underwent transsphenoi-
dal adenomectomy of a PRL-secreting tumor, after 
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which PRL levels remained elevated. Sperm examina-
with LH and FSH tion revealed azoospermia. 
improved sperm parameters 
Treatment 
and his wife conceived 6 
months after the start of treatment. 
This review on the literature considering sperma-
togenesis in men with prolactinornas reveals that 
sometimes sperm abnormalities, both quantitative and 
qualitative, are present. It remains unclear whether 
the sperm abnormalities or infertility may be explai-
ned by the elevated PRL levels or by suppression of 
LH, FSH and testosterone. 
2.4. Adrenals 
Following the recognition in some female patients 
of the association of hyperprolactinemia with mild 
hirsutism, there has been a search for abnormal adre-
nal steroid production. To study effects of PRL on 
adrenocortical function, 
(DHA), dehydroepiandrosterone 
dehydroepiandrosterone 
sulphate (DHAS), an-
drostenedione and testosterone were measured in serum 
obtained from hyperprolactinemic women (Carter et 
al., 1977). DHAS in hyperprolactinemic women was 
slightly higher than in controls (p<0.02). Vermeulen 
et al. (1977) described increased DHA and DHAS levels 
in young women with prolactinomas. High levels for 
DHA were also found in 3 post-menopausal hyperprolac-
tinemic women, and for DHAS in two of them. In 7 
males with a PRL-secreting pituitary tumor only DHAS 
levels were significantly increased compared to nor-
mal controls (Vermeulen & Ando, 1978). Similar ob-
servations were presented by others (Giusti et al., 
1978; Kandeel et al., 1978; Jones et al., 1980; 
Lobo et al., 1980; Seki & Kato, 1981). Other inves-
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tigators have 
DHAS (Parker 
Metcalf et 
not found elevated levels of DHA and 
et al., 1977; Thorner & Besser, 1978; 
al., 1979; Turpin et al., l979a; 
Belisle & Menard, 1980' Drucker & r:avid, 1980' 
Facchinetti et al., 1980). Administration of ovine 
PRL to 3 normal men did not increase DHA, DHAS and 
testosterone concentrations (Varma et al., 1977). 
3. Hyperprolactinemia not related to pituitary tumors 
It is now well established that hyperprolactinemia 
is caused by or associated with a variety of patholo-
gic states such as hypothalamic disorders, Cushing• s 
disease, acromegaly, hypothyroidism, renal diseases, 
drugs etc. (Besser & Thorner, 1976; Lamberts et al., 
1978; Frantz, 1978; del Pozo & Brownell, 1979). 
3.1. Drug-induced hyperpro/actinemia 
Several drugs have been used to induce hyperpro-
lactinemia and to investigate its effects on repro-
ductive functions. 
Suppressed testosterone levels were ·found in men 
in whom hyperprolactinemia was induced by metoclo-
pramide (Carter & Friesen, 1976). In another study, 
Magrini et al. (1979) reported a decreased conversion 
of testosterone into DHT after injection of a 
long-acting testosterone preparation during rnetoclo-
prarnide-induced hyperprolactinemia. 
Metocloprarnide had no effect on either basal lev-
els of LH, FSH and testosterone or the response of LH 
and FSH to LRH (Falaschi et al., 1978). 
Treatment with metoclopramide did not reveal any 
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effect on spermatograms (Dorow et al., 1981), al-
though a short term increase of total sperm count was 
seen l week following initiation of metoclopramide 
treatment (Jecht et al., 1980). 
When hyperprolactinemia was induced by sulpiride 
in normal volunteers, the increase of serum testos-
terone levels in response to hCG was significantly 
higher (Ambrosi et al., 1976). The increase of DHT 
levels in response to hCG appeared to be diminished 
(Magrini et al., 1976). Recently it was shown that 
the increase of both testosterone and DHT in response 
to hCG was significantly higher in men with 
sulpiride-induced hyperprolactinemia (Martikainen & 
Vihko, 1982). 
Haloperidol-induced hyperprolactinemia was able to 
raise basal testosterone levels (Rubin et al., 1976; 
1978). Infusion of haloperidol was able to suppress 
the LRH-induced release of LH (del Carmen Diaz et 
al., 1981). 
It can be concluded from these studies that drug-
induced hyperprolactinemia in healthy men may lead to 
increased basal or hCG-stimulated testosterone lev-
els. Some observations also suggest a suppression of 
Sa-reductase activity in hyperprolactinernic states. 
Further, a direct effect of the drugs on hypothala-
mic, pituitary and testicular functions may also be 
possible. 
3.2. Hyperprolactinemia in renal disease 
The kidney is the main site of PRL elimination 
(Bauer et al., 1980). In 16 out of 21 consecutive 
adult male patients with chronic renal failure PRL 
levels were elevated (Hagen et al., 1976). Impotence 
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was found in 11 of these 21 patients but plasma PRL 
levels were elevated in only 6 of the 11 impotent 
men. Three patients had gynecomastia and elevated 
PRL levels, none had galactorrhea. LH was decreased 
in 3 patients, FSH wat not decreased in any of the 
patients but was elevated in 15 of 21 patients. In 
other series hyperprolactinemia not attributable to 
drugs was found in 60 out of 349 patients of both 
sexes with renal disease, comprising 210 patients 
with impaired renal functions, 87 with moderate 
chronic renal failure and 52 with severe chronic 
renal failure (Cowden et al., 1978), in 14 of 18 pa-
tients with chronic renal failure (Lim et al., 1979) 
and in 7 of 33 men with end-stage renal failure 
(Gomez et al., 1980). In the last series information 
on libido and potency was obtained from 22 out of 33 
men investigated. Elevated PRL levels were present 
in 6 men with a normal potency and in 6 men with im-
potence. An association of clearly elevated PRL lev-
els and impotence, has also been found by others 
(Gura et al., 1980). 
In approximately one third of the hyperprolacti-
nemic subjects with renal failure normal levels of LH 
despite low testosterone levels were observed (Gomez 
et al., 1980). Treatment with bromocriptine resulted 
in an increase in basal LH, suggesting an effect of 
PRL on the pituitary (Gomez et al., 1980). Bommer et 
al. (1981) showed that administration of bromocrip-
tine to uremic men raised testosterone levels without 
affecting LH, suggesting a direct action of PRL on 
gonadal function. 
Subnormal levels of DHA were found in ll men with 
end-stage renal disease (Zumoff et al., 1980). 
Hyperprolactinemia seemed also to be involved in sup-
pression of basal testosterone levels in patients 
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with acute renal failure (Kokot et al., 1982). 
A direct toxic effect of ureum on reproductive 
functions cannot be ruled out in all these studies. 
4. Infertility, impotence and hyperprolactinemia 
Hyperprolactinernia may be found in patients with 
infertility, impotence, hypogonadism and galactor-
rhea. Numerous studies have been performed to inves-
tigate the incidence of hyperprolactinemia and to 
elucidate the relation between the complaints and hy-
perprolactinernia. Hyperprolactinemia does not appear 
to be a common cause of infertility or impotence in 
the male (Table 1.3). 
The incidence of hyperprolactinemia varies widely in 
these series, which seems to depend on the composi-
tion of the group studied and on what is considered 
to be the normal range for plasma PRL (Hermanns & 
Hafez, 1981). 
5. PRL and seminal plasma 
In 1975 PRL was detected in human semen, using a 
radioimmunoassay (Sheth et al., 1975) and its concen-
tration turned out to be four to seven times higher 
than in serum. Decreased PRL concentrations have 
been shown in seminal fluid of oligozoospermic and 
azoosperrnic men compared to normal men (Sheth et al., 
1975; Koskimies et al., 1978; Merino et al., 1980). 
Although a positive correlation between semen PRL 
levels and sperm count could be demonstrated by some 
authors (Sheth et al., 1974; Biswas et al., 1978; 
Schoenfeld et al., 1979; Smith et al., 1979; 
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TABLE 1. 3 Incidence of hyperprolactinemia in men with 
reproductive dysfunctions. 
syndrome 
infertility 
impotence 
incidence 
% 
40 
9 
8 
4 
3 
1 
< 1 
16 
7 
< 1 
references 
Boucher et al. , 
Hermabessiere et al., 
Roulier et al. , 
Mattei & Roulier, 
Masala et al.r 
Segal et al. , 
Segal et al. , 
Hargreave et al., 
As four et al. , 
Blacker et al. , 
Koskimies et al., 
Pierrepoint et al., 
Rjosk & Schill 
Abyho1m & Mo1ne, 
Gray et al., 
Laufer et al., 
Ambrosi et al., 
Spark et al. , 
Krause, 
Rjosk & Schill, 
Miller et al., 
1977 
1977 
1978 
1977 
1979 
1979 
1976 
1977 
1977 
1977 
1978 
1978 
1979 
1980 
1980 
1981 
1980 
1980 
1978 
1979 
1980 
Suchanek & Lcnghino, 1981), it was not observed by 
others (Luqman et al., l979a; To lis et al., 1979; 
Kti qiikkomiircii et al., 1980; De ricks-Tan et al., 1977; 
Fossati et al., 1979). 
PRL added in vitro to semen of fertile donors result-
ed in an increase of cyclic AMP levels, and in incre-
ased utilisation of fructose and the oxydation of 
glucose by spermatozoa, processes which are essential 
for the motility of spermatozoa (Shah et al., 1976; 
Pedron & Giner, 1978; Velazquez-Ramirez et al., 
1980). 
It is known that there is an association between 
ATP-ase activity and sperm capacitation, and it is 
therefore of interest that ATP-ase activity was 
mulated by PRL in vitro (Sheth et al., 1979). 
sti-
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In order to investigate the source of PRL in semi-
nal fluid several studies have been done. There is a 
correlation between PRL concentrations and fructose, 
which suggests that seminal vesicles are secreting or 
concentrating PRL (Krause, 1977). Support of this 
view has come from Segal et al. (1978) who investi-
gated sperm samples obtained by split-ejaculation, 
and found PRL levels which were higher in the second 
than in the first fraction. In congenital absence of 
the vasa and seminal vesicles seminal PRL was marked-
ly depressed (Schoenfeld et al., 1979). Most con-
vincing is the work of Luqman et al. (1979b,c) who 
studied men before and after undergoing elective va-
sectomy and concluded that the accessory sex glands 
were the major source of seminal PRL. 
The possible significance of seminal PRL in hyperpro-
lactinernic states is not understood. 
6. Therapy 
The current management of hyperprolactinemia con-
sists of administration of dopamine-agonistic drugs, 
operative treatment and radiotherapy (von Werder et 
al., 1980). 
Some studies (Table 1.4) report correction of repro-
ductive dysfunctions by lowering PRL concentrations 
to normal irrespective of the mode of therapy. 
No effect on infertility was seen in 4 hyperpro-
lactinemic men treated with bromocriptine (Madsen et 
al., 1980). Laufer et al. (1981) reported improve-
ment of sperm motility and conception during treat-
ment of 3 hyperprolactinemic men with bromocriptine. 
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TABLE 1. 4 Normalization of PRL levels and effects on 
reproductive functions. 
1. restoration of libido and 
potency 
2. improvement of 
gonadotropins 
3. increase of testosterone 
levels 
4. improvement of sperm 
qualities 
5. normalization of DHA 
levels 
Fonzo et al. , 
Saidi et al., 
Thorner et al. , 
Buvat et al., 
Carter et al. , 
Franks & Jacobs, 
Nagulesparen et al., 
Pierini et al., 
Pont et al., 
Thorner et al. , 
Grisoli et al., 
Besser & Thorner, 
Ponzo et al., 
Hermabessiere et al., 
Saidi et al. , 
Buvat et al., 
Carter et al. , 
Nagulesparen et al., 
Pont et al., 
Arafah et al., 
Besser & Thorner, 
Hermabessiere et al., 
Saidi et al., 
Nagulesparen et al., 
Vermeulen & Ando, 
7. Conclusions and aim of the clinical studies 
1977 
1977 
1977 
1978 
1978 
1978 
1979 
1979 
1979 
198Da 
1981 
1976 
1977 
1977 
1977 
1978 
1978 
1979 
1979 
1981 
1976 
1977 
1977 
1979 
1978 
Most of the studies mentioned suggest effects of 
PRL excess in male reproduction. No study is conclu-
sive in showing the mechanisms which may be involved 
in hyperprolactinernic men. Various aberrations in 
hypothalamic, pituitary and gonadal functions have 
been described. The purpose of the work described in 
this thesis was to further investigate some aspects 
of male hyperprolactinemia. 
The following questions may be asked: 
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1. Does hyperprolactinernia cause loss of libido and/ 
or potency? 
2. Does hyperprolactinemia directly interfere with 
spermatogenesis? 
3. Why do a significant number of hyperprolactine-
mic men have low blood levels of testosterone? 
4. Why do hyperprolactinemic men with low testoster-
one blood levels have normal basal gonadotropin 
levels and mostly a normal increase during stimu-
lation with LRH? 
To answer these questions two groups of patients 
were investigated. The first group consisted of men 
with a PRL-secreting pituitary tumor, the second 
group were men visiting our out-patient department 
for infertility. The results of this clinical study 
will be presented in Chapter 3. 
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CHAPTER 2 
PRL AND REPRODUCTIVE FUNCTIONS IN MALE RATS 
1. Introduction 
In search of the physiological role of PRL in re-
productive functions of male mammals, much attention 
has been paid to the possible involvement of PRL in 
the growth of the testes and the accessory sex 
glands. During sexual development of the male rat 
PRL levels rise at day 25 and remain relatively con-
stant until day 50. Initiation of the rapid phase of 
testicular growth at 25 days is correlated with an 
elevation of serum FSH and PRL levels. Rapid growth 
of the accessory sex glands begins somewhat later in 
the presence of high PRL levels, falling FSH levels 
and gradually increasing LH levels, suggesting a syn-
ergism between PRL and LH-stimulated testicular an-
drogens (Negro-Villar et al, 1973). Administration 
of PRL to hypophysectomized male Sprague-Dawley rats 
elicited minimal growth of the seminal vesicles, but 
none of the prostate (Chase et al., 1957). From re-
sults of this study a synergism of PRL with testos-
terone in stimulating growth of male accessory sex 
glands was suggested. 
PRL alone can also influence testicular and/or ac-
cessory sex organ function as has been 
deficient animals 
clearly 
(see 
demon-
review strated 
Bartke, 
in PRL 
l980a). Administration of PRL to dwarf mice, 
which have PRL deficiency and LH and FSH deficiency, 
was followed by growth of the testes and the accesso-
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ry reproductive glands, 
terone production and 
al, 1965, 1966, l970a-b, 
increased testicular testes-
induced fertility (Bartke et 
1971, 1975, l977a-c, l980a). 
Recently an increased release of FSH was also ob-
served during treatment with PRL in these PRL defi-
cient animals (Bartke et al., l98la). 
In the male golden hamster, testicular atrophy can be 
induced by exposure to short photoperiod, which is 
also accompanied by a decrease of plasma PRL levels. 
PRL administration to these animals was followed by 
growth of the testes (Bartke et al., 1975; l980b) 
and by an increase of plasma FSH levels (Bartke et 
al., l98lb). 
It can be concluded from these studies that testis 
growth and testicular functions are regulated 
ious adenohypophyseal hormones including PRL 
et al., 1978; Lipsett, 1980). 
by var-
(Bartke 
There is evidence that PRL alone, in the absence 
of testosterone has no effect on prostatic growth and 
this suggests that the synergistic action of PRL with 
testosterone is mediated by the action of testoster-
one (Holland & Lee, 1980). 
The next paragraphs will deal with interactions 
between PRL, gonadotropins and androgens and with the 
effects of PRL on gonads, accessory sex glands and 
adrenals in male rats in physiological and hyperpro-
lactinemic conditions. 
2. Physiological role of PRL 
2.1. Testes 
There is some evidence that PRL can enhance the 
stimulation of the androgen secretion by LH in hypo-
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physectomized rats. Both the measurement of androgen 
secretion and administration of PRL were carried out 
in different ways. 
Hafiez et al.; (1971) showed that administration 
of PRL subcutaneously (s.c.) together with LH to hy-
pophysectomized rats was able to normalize the activ-
ity of 3~-hydroxysteroid-dehydrogenase in the testes. 
It was shown by the same authors (Hafiez et al., 
1972a) that treatment of hypophysectomized rats with 
PRL and LH resulted in an increased conversion of 
acetate into testosterone in minced testes of these 
animals, which conversion was enhanced even more than 
after treatment with LH alone. 
alone had no effect. 
Treatment with PRL 
By estimating the androgen production by the 
testes using either plasma testosterone levels (Hafi-
ez et al., 1972b; Bartke & Dalterio, 1976) or sex 
accessory organ weight, Balin & Schwartz (1972) and 
Johnson (1974) found that PRL augmented the testicu-
lar response to LH when both hormones were given sim-
ultaneously. 
The presence of.ectopic pituitary transplants in 
hypophysectomized rats caused PRL levels, which were 
also able to increase testicular sensitivity to LH. 
Lu et al. (1977) showed that pituitary grafts under 
the kidney capsule partially prevented atrophy of the 
testes and ventral prostate. Small amounts of LH and 
FSH could be detected in peripheral plasma of hypo-
physecytomized animals with pituitary grafts, while 
both LH and FSH were undetectable in the plasma of 
hypophysectomized rats without pituitary grafts, an 
observation confirmed by Lam et al. (1976). 
Furthermore, treatment of the pituitary grafted ani-
mals with a dopamine agonistic agent did not alter 
either LH and FSH levels, or testis and ventral pro-
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state weight. This observation suggests that PRL 
alone had no effect on the testes and the accessory 
sex glands, but that prevention of testicular atrophy 
in hypophysectomized animals is due to the presence 
of small amounts of LH and FSH in peripheral plasma, 
secreted by the pituitary grafts. 
PRL given subcutaneously for over 30 days to hypo-
physectomized rats had no effect on the maintenance 
of spermatogenesis (Bartke & Lloyd, 1970b). Admini-
stration of PRL to hypophysectomized rats did not in-
crease the reduced numbers of spermatids and pachy-
tene spermatocytes (Sivelle et al., 1978). 
The maintenance of spermatogenesis in hypophysectom-
ized rats by ectopic pituitaries (Lu et al., 1977) 
can also be explained by the presence of small am-
ounts of LH and FSH in peripheral blood as mentioned 
above. 
Some work on the effects of PRL on spermatogenesis 
have been done in intact rats. 
Suppression of PRL levels in intact adult male rats 
with bromocriptine did not reveal a role for PRL in 
initiating or maintaining spermatogenesis in the rat 
(Alger et al., 1975). It was shown by Nag et 
al. (1981) that suppression of PRL with bromocriptine 
in immature rats resulted in an inhibition of the 
conversion of spermatocytes into spermatids. 
2.2. Accessory sex glands 
Grayhack & Lebowitz (1967) showed that PRL in com-
bination with testosterone stimulated the growth of 
the lateral lobe of the prostate in hypophysectomized 
-orchidectomized rats. Implantation of one pituitary 
under the kidney capsule in castrated, castrated-
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adrenalectomized and castrated-hypophysectomized rats 
was not followed by a rise of the weights of prostate 
and seminal vesicles (Bartke & Lloyd, l970a). The 
weights of dorso-lateral prostates of castrated rats 
treated with testosterone propionate were signifi-
cantly heavier when PRL was also administered (Moger 
et al., 1973). PRL did not increase the effect of 
testosterone on the weight of the seminal vesicles. 
Stimulation of the functional activity of the pro-
state by PRL-testosterone synergism was suggested, 
since an increase of the zinc content of the 
dorso-lateral prostate was found. 
Treatment with PRL of hypophysectomized-castrated, 
testosterone-substituted rats significantly increased 
the nuclear levels of DHT in both the head of the ep-
ididymis and ventral prostate (Baker et al., 1977). 
Other confirmation of PRL-testosterone synergism was 
the finding of a significant increase of prostatic 
RNA and DNA concentration in normal and castrated 
rats after treatment with PRL (Thomas & Manandhar, 
1975). 
A marked increase in the weight of prostate trans-
plants was seen during treatment of the male host 
with testosterone together with PRL (Edwards & Tho-
mas, 1980). 
Injection of PRL alone to intact male rats caused 
a small although significant increase of the weight 
of the dorsal lobes of the prostate (Thomas & Manan-
dhar, 1977). 
Furthermore, the finding that PRL alone could in-
crease the uptake of 65 zn by the dorso-lateral pro-
state of castrated rats indicates an effect of PRL 
independant of testosterone (Moger et al., 1972). 
No augmentation by PRL of the effect of testoster-
one upon prostates and seminal vesicles in hypophy-
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sectomized rats was found by Johnson (1974). 
Administration of PRL to hypophysectomized rats had 
also no effect on prostatic weight (Yamanaka et al., 
1975) In hypophysectomized rats treated with tes-
tosterone prostatic Su-reductase activity was equal 
to that in intact controls; when PRL was given to-
gether with testosterone Sn,--reductase activity was 
doubled. 
When PRL was given (without testosterone) to intact 
rats Srr-reductase activity did not increase, but de-
creased (Yamanaka et al., 1975). 
These controversial effects of PRL on the accesso-
ry sex glands do not justify the opinion that PRL 
alone or with testosterone has merely a sti.mulatory 
effect. Moreover, the results of the experiments in 
hypophysectomized animals have to be interpreted with 
caution~ since hardly any PRL levels have been menti-
oned. It has been observed that even very small rem-
nants of pituitary tissue in the sellar fossa after 
hypophysectomy are able to induce hyperprolactinemia 
(van Straalen et al., 1981). 
3. Hyperprolactinemia 
The finding of an association between hyperprolac-
tinemia and hypogonadism in men gave rise to a re-
newed interest in the possible effects of elevated 
PRL levels on reproductive functions in male animals. 
Implantation of a PRL-secreting tumor into adult 
male rats resulted in severe testicular atrophy with-
in months (Wilson, 1971; Fang et al., 1974; Hodson 
et al., 1980). The concentration of testosterone was 
very much decreased, the weight of the testes de-
clined to less than half of the control value and the 
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weight of the accessory reproductive glands decreased 
to one fourth (Fang et al., 1974). Very low levels 
of serum LH were measured (Hodson et al., 1980). 
However, there are remarkable differences between 
these observations obtained with a pituitary tumor 
and the results obtained with multiple ectopic grafts 
of normal pituitary tissue. Both conditions result 
in hyperprolactinemia, but the level obtained is much 
lower in the latter situation. Also in that situa-
tion testes weight and plasma testosterone levels did 
not change, whereas seminal vesicles significantly 
grew larger (Bartke, l977b). 
3.1. Gonadotropins 
In 1937 a pronounced antigonadal action of PRL was 
found in adult pigeons, which was explained by a di-
rect action of the administration of PRL on the pitu-
itary, with suppression of FSH release (Bates et al., 
1937). 
Both serum LH and FSH levels were decreased when 
hyperprolactinemia was induced in male rats by two or 
more pituitary gland transplants under the kidney 
capsule (McNeilly et al., 1978). An increase in FSH 
levels was seen in intact rats, made hyperprolacti-
nemic by 2 pituitary grafts (Tresguerres & Esquifino, 
l98lb). 
Injections of PRL, implants of PRL in the median 
eminence and pituitary grafts under the kidney cap-
sule could partially inhibit the rise of serum LH 
after castration of male rats (Grandison et al., 
19 77; 
1978; 
Celotti et al., 1978; 
Tresguerres et al., l98la). 
Winters & Loriaux, 
Treatment of cas-
trated male rats with PRL injections had no effect on 
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FSH levels (Celdtti et al., 1978). 
Another indication that PRL presumably acts di-
rectly at the pituitary level, was a diminished res-
ponse of LH after LRH administration to hyperprolac-
tinemic rats (Gudelsky et al., 1976; Grandison et 
al., 1977; 
Tresguerres, 
Winters & Loriaux, 1978; Esquifino & 
1979; Greeley & Kizer, 1979; McNeilly 
et al., l980a; Tresguerres & Esquifino, l98lb). 
3.2. LRH and dopamine in hyperprolactinemia 
The role of PRL in the regulation of LH and FSH 
secretion is currently of great interest, especially 
in female rats (Smith, 1980). The mechanism by which 
high blood levels of PRL lead to suppression of gona-
dotropin secretion is unknown. Several hypotheses 
have been proposed (Porter et al., 1980): 
l. PRL could act directly on the gonadotropin secre-
ting cells to suppress gonadotropin secretion. 
2. The inhibitory effect of PRL on gonadotropin se-
cretion could be mediated by the hypothalamus. 
Hyperprolactinernia induced in the rat by a PRL-
secreting tumor (MtTWS) or by ectopic pituitary 
grafts increased the hypothalamic LRH stores and 
blocked the discharge of LRH from the hypothalamus, 
which follows castration (Gil-Ad et al., 1978; 
Grandison et al., 1977). An increase of hypothalamic 
content of LRH has also been reported in intact male 
rats bearing a PRL- and growth hormone-secreting 
tumor MtTWl5 (Hodson et al., 1980). 
It has been well established that PRL can regulate 
its own secretion, probably mediated by hypothalamic 
dopamine, the most important PRL inhibiting factor 
(Chapter 6 ) . 
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The increased hypothalamic dopamine turnover in reac-
tion to elevated serum PRL levels (Hokfelt & Fuxe, 
1971) has been suggested to inhibit also the release 
of hypothalamic LRH into the portal vessels. A de-
crease of LRH in hypophysial portal blood in hyper-
prolactinemic ovariectomized animals might explain 
that LH did not rise directly after ovariectomy in 
these animals (Beck & Wuttke, 1977). 
Hyperprolactinemia results in increased dopamine lev-
els in hypophysial portal blood (Cramer et al., 
1979), but there is insufficient evidence that this 
increased release of dopamine can suppress the secre-
tion of LH and FSH. 
Some authors reported a decreased pituitary con-
tent of LH (McNeilly et al., 1978), whereas an incre-
ased content was found by others (Hodson et al., 
1980; Lamberts et al., 1981) in hyperprolactinemic 
rats. Also these findings do not offer an explana-
tion for the low blood levels of LH and FSH in hyper-
prolactinemic rats. 
3.3. Testes and accessory sex glands 
Although plasma LH and FSH are suppressed in hy-
perprolactinemic rats, testosterone levels do not 
seem to be affected (Bartke et al., l977a; McNeilly 
et al., 1978; l980a; Tresguerres et al., l98la). 
These observations are in contrast to those in hyper-
prolactinemic men who often exhibit normal serum go-
nadotropin levels and decreased serum testosterone 
levels (Chapter 1). 
Some authors were able to show that PRL has an in-
hibitory effect on the testes in rats. Serum testes-
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terone levels and testosterone secretion by testicu-
lar tissue in vitro in response to the administration 
of hCG in hyperpro1actinemic rats were reduced (Tres-
guerres et a1., 1981a; Sharpe et a1., l980a-b). In 
animal experiments no structural changes in the male 
accessory sex glands during hyperprolactinemia have 
been observed (See review Hermanns & Hafez, 
Chapter 1) . 
4. Receptors 
4.1. Testes 
1981, 
The presence of specific binding sites for PRL on 
the testes has been reported by Aragona & 
Friesen (1975). These receptors were located on Ley-
dig cells (Aragona et al., 1977; Charreau et al., 
1977b) and have led to numerous studies on this sub-
ject. The finding that PRL was able to stimulate 
steroidogenic enzymes in the Leydig cells and to ini-
tiate spermatogenesis, led many investigators to 
study the effects of PRL on receptors. 
Treatment of hypophysectomized rats with PRL (Zipf 
et al., 1978) or with one ectopic pituitary (McNeilly 
et al., 1979) caused a rise of the number of LH re-
ceptors in rat testicular tissue (Purvis et al., 
1979; Bambino et al., 1980). 
The number of LH receptors per Leydig cell in hyper-
prolactinemia was higher than in control rats (Sharpe 
et al., 1979, 1980a-b, Chan et al., 1981). LH nega-
tively regulates its Leydig cell receptor 
(Sharpe & McNeilly, 1979) and the increase in LH 
receptor number in hyperprolactinemia may be due to a 
chronic reduction of LH levels. Increase of LH re-
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ceptor binding in the hypophysectomized rat treated 
with PRL can be explained only by a direct effect of 
PRL on the Leydig cell. Apparently normal serum con-
centrations of testosterone are seen in rats hyper-
prolactinernic through pituitary grafts, which have 
low serum levels of LH. In rats with a PRL-secreting 
found (Hodson tumor very low testosterone levels were 
et al . , 1980 ) ; in these animals serum LH has also 
been found to be low. 
4.2. Accessory sex glands 
PRL binding sites have been demonstrated in the 
ventral prostate of the male rat (Kledzik et al., 
1976; Charreau et al., l977a), in the dorsal pro-
state (Aragona et al., 1977) and in the seminal vesi-
cles (Barkey et al. , 1977;1979). The presence of 
testosterone is essential for the maintenance of PRL 
binding sites in these organs. 
5. In vitro studies with PRL 
Following reports that PRL can stimulate male ac-
cessory sex glands directly, effects of PRL on the 
conversion of testosterone to DHT have been studied 
in the cultured ventral prostates of rats. The re-
sults of such studies are equivocal. Bovine PRL and 
ovine PRL had opposite effects on testosterone uptake 
and metabolism in the rat prostate gland (Lloyd et 
al. , 1973) . These differences 
by differences in the degree of 
were probably caused 
purity of the PRL 
preparations used. PRL did not alter the metabolism 
of testosterone to DHT (Johansson, l976a). According 
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to Manandhar & Thomas (1976) PRL reduced the forma-
tion of testosterone in DHT in the rat ventral pro-
state. 
Johansson (1975) found a greater stimulation of 
the synthesis of RNA and protein by bovine PRL and 
testosterone than with testosterone alone in tissue 
cultures of the rat ventral prostate. 
Adenylate cyclase activity in prostates was stimulat-
ed by ovine PRL (Golder et al., 1972). 
PRL was able to increase the specific binding of DHT 
to the ventral prostate nuclei (Johansson, 1976b) 
In some (Thomas & Keenan, 1976) but not all (Data-
treymurty et al., 1975) studies, stimulation of the 
seminal vesicles by PRL has not been observed as con-
sistently as has been shown for the PRL stimulation 
of the rat prostate. 
6. Adrenals 
Little consideration has been given to a possible 
participation of the adrenal in the inhibition of LH 
and FSH secretion during hyperprolactinemia. It has 
been found by some workers (Greeley & Kizer, 1979) 
that the adrenals may participate in the suppression 
by PRL of the LRH-induced LH-release; others have 
not been able to confirm these findings (McNeilly et 
al., 1980a). 
It has been known for a long time that PRL exerts 
a direct effect on the adrenal cortex. Administra-
tion of PRL combined with ACTH resulted in blood lev-
els of corticosterone which were about one half of 
those caused by ACTH alone (Bates et al., 1964). PRL 
administration in vivo stimulated the production of 
corticosterone by adrenal slices in vitro and inhi-
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TABLE 2.1 Effects of PRL on reproductive functions in the 
male rat. 
1. Physiological effects of PRL 
hypothalamic-pituitary - elevation of plasma FSH levels 
level 
testes - growth of testes during puberty 
accessory sex glands 
adrenals 
2. Elevated PRL levels 
hypothalamic-pituitary 
level 
testes 
adrenals 
- increase of testicular testostero-
ne production; synergism with LH 
- increase of hydroxy-steroid dehy-
drogenase 
- accumulation of esterified choles-
terol 
- increase of number of LH receptors 
- stimulation of spermatogenesis; 
synergism with LH 
- growth of prostate and seminal ve-
sicles during puberty 
- potentiation of the effects of 
exogenous androgens on growth of 
accessory sex glands 
- increase of zinc-uptake in the 
prostate 
- suppression of Sa-reductase acti-
vity in the prostate 
- suppression of Sa-reductase acti-
vity 
- increase of DA in portal venous 
blood 
- blockade of hypothalamic LRH-re-
lease 
- increased hypothalamic LRH-content 
- low levels of LH and FSH 
- normal testosterone production 
- diminished response of testoste-
rone to hCG 
- participation in the suppression 
of LRH-induced LH-release 
3. Extremely elevated PRL levels 
pituitary 
testes 
accessory sex glands 
copulatory behavior 
- suppression of plasma LH and FSH 
- atrophy; low plasma testosterone 
- atrophy 
- suppression (Svare, 1979; Doherty, 
1981, Bailey, 1982) 
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bited the formation of reduced steroid metabolites; 
both effects were probably due to suppression of 
Srt-reductase activity (Witorsch & Kitay, 1972; 
Gustafsson & Stenberg, 1975; Ogle & Kitay, 1979). 
The low rate of corticosterone production by iso-
lated adrenal cells of hypophysectomized rats could 
be partially restored to normal by administration of 
PRL (Lis et al., 1973). 
7. Aims and outlines of experimental studies to be reported in Chapters 4·8 
Although the effects of PRL (Table 2.1) on repro-
ductive functions in rats bearing a PRL-secreting 
tumor and exhibiting high PRL levels are rather uni-
form, the findings in rats with only mild elevations 
of serum PRL levels are equivocal and elicit several 
questions: 
1. How can normal levels of testosterone be present 
in moderately hyperprolactinemic male rats, in the 
presence of decreased gonadotropin levels? 
2. By which mechanisms are gonadotropin levels sup-
pressed? 
3. Do the the adrenals have a role in the suppression 
of gonadotropin secretion in hyperprolactinemic 
male rats? 
4. Can spermatogenesis be suppressed by elevated PRL 
levels? 
To answer these questions hyperprolactinemia was 
induced by a PRL- and ACTH-secreting transplantable 
rat pituitary tumor in adult male rats (Chapters 
4-6). Local effects of PRL on testicular functions 
were studied by using an intra-testicular pituitary 
transplant (Chapter 8). 
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CHAPTER 3 
ASPECTS OF INFERTILITY AND PITUITARY FUNCTIONS 
OF 32 MEN WITH UNTREATED PRL-SECRETING MACRO-
AND MICROADENOMAS 
R.F.A. Weber, S.W.J. Lamberts, J.C. Birkenhager 
1. Introduction 
There is considerable evidence that infertility in 
female patients can be a consequence of hyperprolac-
tinemia. In contrast to women, whose clinical man-
ifestations galactorrhea and amenorrhea - lead to 
early medical consultation, many hyperprolactinemic 
male patients present with headache and visual im-
pairment due to extrasellar extension of a pituitary 
tumor (Carter et al., 1978; Derome et al., 1979; 
Grisoli et al., 1980; Serri et al., 1980). 
Retrospectively, however, loss of libido, impotence, 
galactorrhea and sometimes infertility may be present 
for an extended period (Carteret al., 1978; Franks 
et al., 1978; Nagulesparen et al., 1978; Thorner et 
al., 1978). Although hyperprolactinemia obviously 
seems to exert a suppressive action on reproductive 
functions in men, the incidence of hyperprolactemia 
among men with impotence (Miller et al., 1980; Spark 
et a1., 1980) or infertility (Hargreave et al., 1977; 
Segal et al. 1979; Abyholm et al., 1980; Laufer et 
al., 1981) has been reported to be very low. 
Moreover, it has not yet been established whether the 
symptoms in hyperprolactinemic men are due to the 
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elevated PRL levels itself, to the accompanying hypo-
gonadism or to compression and/or local destruction 
of the sellar region by the pituitary tumor with loss 
of normal pituitary function (Hermanns & Hafez, 1981; 
Perryman et al., 1981). 
Serum gonadotropin concentrations are reported to 
be normal in hyperprolactinemic men with microadeno-
mas despite decreased serum testosterone levels (Car-
ter et al., 1979; Franks et a1., 1978; Thorner et 
al., 1978; Spark et al., 1982) and they appear to 
respond normally to LRH (Carteret al., 1978; Franks 
et al., 1978; Prescott et al., 1982). In contrast, 
decreased basal serum gonadotropin levels and a 
blunted response to LRH have been reported in men 
with PRL-secreting macroadenomas of the pituitary 
(Nagulesparen et al., 1978; Grisoli et al., 1980; 
Eversmann et al., 1981; Hermanns & Hafez, 1981). 
Assessment of the other anterior pituitary functions 
also revealed pituitary insufficiency in this type of 
patient (Klijn et al., 1980). 
Azoospermia, oligozoospermia, norrnozoospermia and 
polyzoospermia have all been reported in hyperprolac-
tinemic men (Snyder et al., 1979); however, little 
is known about fertility in these men. 
The aim of the present study was to investigate 
the mechanism by which elevated PRL levels might at-
tribute to infertility and/or altered sperm qualities 
in relation to tumor size, and other pituitary func-
tions. Moreover, the effects of normalization of PRL 
levels on fertility were studied. 
2. Patients and methods 
Thirty-two men with hyperprolactinemia were stu-
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died. All conditions and medications that have been 
recognized as principal causes of functional hyper-
prolactinemia were excluded. They were divided in 
two groups according to their symptoms. In the first 
group (group I) these symptoms consisted exclusively 
of visual disturbances, headache or symptoms of hypo-
pituitarism and clinical evidence of the presence of 
a pituitary tumor was obtained in all 19 patients. 
Group II consisted of thirteen out of a group of 598 
patients attending our department of male infertili-
ty. 
The clinical work-up consisted of a detailed his-
tory and physical examination. All patients un-
derwent frontal and lateral plain skull radiography, 
lateral polytomography of the sellar region at inter-
vals of 2.5 mm, and when indicated a computerized 
axial tomography (CAT) of the suprasellar region 
and/or pneumoencephalography in order to visualize 
suprasellar and parasellar extension of the pituitary 
tumor. Visual fields were plotted with a Goldman ap-
paratus. Ophthalmologic evaluation was completed 
with fundoscopy and visual acuity. Basal PRL levels 
and the PRL response to the intravenous administra-
tion of 200 microgram thyrotropin-releasing hormone 
(TRH) (Hoechst, Amsterdam, The Netherlands) was meas-
ured in all patients- Anterior pituitary function 
was assessed by the determination of serum testoster-
one levels and the response of serum LH and FSH to an 
intravenous bolus of 100 microgram LRH (Hoechst); 
serum thyroxine (T 4 ) and thyroid-stimulating hormone 
(TSH) response to 200 microgram Truo; plasma 
ll-deoxycortisol (Compound S) after administration of 
6 x 750 mg metyrapone orally in 24 hours. For com-
parison LRH was also given to nine volunteers and 
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blood was sampled. When it was possible to obtain an 
ejaculate, semen analysis was performed. 
To investigate the question, whether lowering of 
serum PRL levels would restore fertility, ll patients 
of group II were treated with bromocriptine. 
2.1. Hormone assays 
Plasma PRL levels were determined by radioimmuno-
assay, using a commercial kit purchased from IRE 
(Fleurus, Belgium). Normal values range up to 
12 ,ug/1 in normal men. The normal PRL response to 
TRH has previously been described (maximal increment: 
22.9 + 17.6 ,ug/1; %increase: range 102 to 1646%; 
Klijn et al., 1981). 
Serum testosterone levels were measured by RIA 
(normal values: 0.35 to 0.80 l'g/dl) (Verjans et al., 
1973). 
Serum LH and FSH were estimated by a double anti-
body RIA, using standard preparations WHO 69/104. In 
our assay system for LH, 1 U of the WHO standard 
69/104 corresponds to 3.8 U of the WHO standard 
68/40. Basal levels of LH and FSH varied from 0.6 
2.5 U/1 and from 0.7 - 3.3 U/1 respectively (Klijn et 
al., 1980). 
Serum T4 and TSH were measured by radioimmunoassay 
techniques as described before (Klijn et al., 1980; 
Visser et al., 1975). Normal basal levels of T4 and 
TSH were 60 - 140 nMol/1 and < 1 - 4.9 mU/1 respec-
tively. An increase of TSH of at least 5 mU/1 has 
been accepted to be a normal reaction 30 minutes 
after an i.v. bolus of TRH. 
Compound S (normal values after metyrapone ad-
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ministration >10 ,ug/dl) was measured by competitive 
protein binding assay (Meikle et al., 1969). 
2.2. Statistical procedures 
Values are given as the mean + S, E. M TRH and 
LRH tests were subjected to an analysis of variance. 
When significant overall effects were obtained, corn-
parisons between or within groups were made using 
Duncan's multiple range test. Otherwise a non-para-
metric test (Mann-Whitney U) was used to establish 
differences between the two groups. Differences were 
considered to be significant when P<0.05. 
3. Results 
The mean age of group I (41.4 years: range 15 to 
64 years) was significantly different (P<0.005) from 
group II (30.3 years: range 24 to 54 years). 
The presenting symptoms are summarized in Table 3.1. 
TABLE 3.1 Clinical features of 32 untreated hyperprolacti-
nernic men referred with complaints of a pituitary 
tumor (group I) and infertility (group II). 
headache 
visual impairment 
impotence 
loss of libido 
galactorrhea 
panhypopituitarism 
infertility 
total 
a diminished libido b 
group I 
n % 
10 53 
8 42 
12 67 
9 56 
3 16 
4 21 
n.k.b 
19 
not known 
group II 
n 
2 
2 
13 
13 
% 
100 
73 
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All patients in group I had macroadenomas, with su-
prasellar extension in 68% and bone destruction of 
the sellar fossa in 58% of the patients. In 67% of 
these patients impotence was noted. Only 2 patients 
in group II showed enlargement of the sella turcica, 
one with suprasellar extension. Interesting in this 
respect was the presence of diminished libido in 
these 2 patients. The sella turcica was asymmetrical 
in 54% and normal in 31% of the patients of group II. 
Basal PRL levels in group I (982 ~ 294 ~g/1) were 
significantly (P<0.005) higher than in group II 
(42 + 8 g/1). 
The absolute TRH stimulated PRL levels and the % in-
crease (% of initial value) of PRL are given in Table 
3 0 2. In both groups PRL levels increased after stim-
1D JO 00 
minute> 
10 30 00 
minutes 
Fig. 3.1 Basal serum LH levels and their response to 100 vg LRH i.v. 
in 19 hyperprolactinemic men with macroadenomas (o-o), 13 hyperpro-
lactinemic infertile men (e-el and 9 controls (e·····•l. Absolute LH levels 
(left) and % increase of LH (right) are given as mean ± 5. E. M. 
p<O.OS vs. control and group II. 
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ulation with TRH- The % increase of PRL in group I 
was significantly less than in group II. 
Serum testosterone levels in group I (0.20 :':. 0.04 
l'g/dl) were significantly (P <0. 005) lower than in 
group II (0. 40 :':. 0. 04 ,ug/dl). Testosterone levels 
less than 35 pg/dl were noted in 15 patients of group 
I, but in only 5 patients in group II. 
Basal and LRH stmulated LH levels are given in 
Figure 3. 1. 
of LH between 
II. However, 
There was no difference in basal levels 
the control group and group I or group 
basal levels of LH in group II were 
significantly higher than in group I. 
showed an increase of LH after LRH. 
All groups 
J _______ J 
~ 
" minutes 
L _____ J 
// 
I 
I 
I 
! 
I 
" minutes 
Fig. 3.2 Basal serum FSH levels and their response to 100 119 LRH i.v. 
in 19 hyperprolactinemic men with macroadenomas {o-o), 13 hyperprolac-
tinemic infertile men (e-•) and 9 controls (•····•). Absolute FSH levels 
(left) and %increase of FSH (right) are given as mean± S.E.M. 
p<O.OS vs. control. 
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There was no difference between group II and the con-
trol group with regard to the % increase of LH, which 
was significantly less in group I. The absolute max-
imal increment of LH was also significantly decreased 
in group I (P<0.025). 
Basal levels of FSH either in group I or group II 
were not different from those in the control group, 
although basal levels of FSH in group II were signi-
ficantly higher than in group I. Administration of 
LRH resulted in an increase of FSH in all groups 
(Figure 3.2). 
In group I the % increase of FSH was only 30 minutes 
after stimulation lower than in the control group. 
20 30 00 
minute> 
Fig. 3. 3 TSH levels (left) and % increase of TSH (right) in response to 
an i.v. bolus of 200 ].19 TRH in 19 hyperprolactinemic men with macroade-
nomas (o-o) and 13 hyperprolactinemic infertile men (e-o). Values are 
given as mean± S.E.M. 
p<O.OS 
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The absolute maximal increment of FSH in group I was 
significantly less compared to the control group 
(P<0.005) and group II (P<O.OOl). 
Seven patients in group I showed a decreased level 
of T4 , against none of the patients in group II. The 
mean level of T4 in group I (72.9 ~ 7.5 nMol/1) was 
significantly lower than in 
nMol/1). Although the levels 
group 
of TSH 
II (102~8.8 
significantly 
increased after TRH administration (Figure 3.3) in 
group I and group II, the % increase of TSH in group 
I was significantly less than in group II. A blunted 
response of less than 5 mU/1 30 minutes after an i.v. 
bolus of TRH was seen in 15 patients in group Ip in 
none of the patients in group II. 
Compound s levels less than 10 l'g/dl were observed 
in 3 of 15 patients in group I, but in none of group 
II. The mean value of Compound s in group I 
( 15. 1 + 1.8 l'g/dl) was significantly lower than in 
group II (22.8 ~ 2-7/'g/dl). 
Spermanalyses of both groups are given in Table 
3.3. These analyses could be assessed in only 4 pa-
tients of group I, who were able to ejaculate. All 
parameters were normal with the exception of deere-
ased motility in all 4 specimens. One of these pati-
ents became father several weeks before admission to 
our hospital. Two patients of group II (patients l 
and 12) fathered wihout any therapy several months 
after diagnosis. The wives of 4 men treated with 
bromocriptine conceived during therapy as shown in 
Table 3.4. A small but significant (P<0.05) rise of 
the serum testosterone level was present in all these 
4 patients. Another 6 patients were treated with 
bromocriptine; PRL levels normalized but conception 
was not achieved. In l patient bromocriptine could 
not be administered because of adverse side effects. 
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TABLE 3.3 Sperm qualities of 13 untreated hyperprolactine-
mic men referred because semen abnormalities 
were suggested to be the cause of their inferti-
lity and of 4 men with PRL-secreting rnacroadeno-
mas (a-d). 
patient volume cougt motility normal spermatozoa 
ml xlO ;ml % % 
1 6 1.2 0 48 
2 4 25 25 15 
3 2 2 10 5 
4a 4 <1 0 24 
5a 2 10 5 21 
6 3 15 35 26 
7 5 < 1 30 2 
8 8 ll 30 18 
9 3 < 1 0 1 
10 5 10 10 21 
ll 5 90 10 34 
12 3 60 10 41 
13 8 7 10 9 
a 2 138 20 6 
b 3 30 30 23 
c 1.5 275 25 21 
d 3.5 30 15 8 
a 
macroadenomas 
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4. Discussion 
In the present study impotence and loss of libido 
was especially associated with a PRL-secreting macro-
adenoma of the pituitary and high PRL levels The 
majority of these patients, however, was referred 
with symptoms of visual impairment, headache or hypo-
pituitarism. Both impotence and loss of libido were 
absent in 11 infertile patients of group II display-
ing only moderately increased PRL levels~ In this 
group of patients the diagnosis PRL-secreting microa-
denoma was made by excluding other causes of hyper-
prolactinemia. 
ased libido 
Two patients, who experienced deere-
showed an enlarged sella turcica. 
Previous reports have indicated that impotence, loss 
of libido and hypogonadism are considered to be com-
mon clinical features of hyperprolactinemia in men 
with PRL-secreting pituitary adenomas, but that the 
presenting symptoms are often related to local expan-
sion of the tumor (Carteret al., 1978; Franks et 
al., 1978; Nagulesparen et al., 1978; Thorner & 
Besser, 1978; Derome et al. , 1979; Grisoli et al. , 
1980; Serri et al., 1980; Spark et al., 1982). In 
our study testosterone levels were decreased in the 
patients with macroadenomas (group I), but mostly 
normal in group II, which might suggest that only 
high levels of PRL are accompanied by low levels of 
testosterone. This is in contrast with a recent re-
port by Spark et al. (1982), who described decreased 
serum testosterone levels in men with microadenomas 
and slightly increased PRL levels. 
The mechanism(s) by which sexual dysfunction and 
hypogonadism develop in hyperprolactinemic men are 
unclear. Low testosterone levels imply either defi-
cient gonadotropin secretion or inhibition of the go-
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nadotropins at the gonadal level by PRL. In our 
study basal levels of serum LH and FSH in hyperpro-
lactinemic men did not differ from the control group, 
which is in accordance with other reports (Carter et 
al., 1978; Peillon et al., 1979). The basal levels 
of both LH and FSH were significantly increased in 
the group of infertile patients with low sperm counts 
compared to group I. This observation is in accor-
dance with a previous report that sperm count is ne-
gatively correlated with FSH and LH (Aafjes et al., 
1977). Nevertheless, a suppressive effect on basal 
gonadotropins in patients with macroadenomas and high 
PRL levels (group I) cannot be denied. A blunted 
response of LH and FSH however was present in group 
I. The response of LH and FSH in group II and the 
control group were not different. Similar results 
have been observed by others (Nagulesparen et al., 
1978; Eversrnann et al., 1981) . Eversrnann et al. 
(1981) showed that 90% of his patients with 
PRL-secreting macroadenomas had an insufficient res-
ponse of LH and FSH to LRH. Other studies however 
report normal LRH tests in men with macroadenomas 
(Franks et al., 1978: Prescott et al., 1982). No 
possible explanation can be given for these contra-
dietary results. Based on the discussion above, it 
seems likely that reduced levels of testosterone are 
due to impaired gonadotropin secretion. However, 
there is also some evidence for a direct effect of 
PRL on the level of the gonads. A fairly quick in-
crease of serum testosterone levels can be observed 
during brornocriptine therapy despite little or no in-
crease of serum LH (Carteret al., 1978). Moreover a 
direct effect of PRL not only on Leydig cell function 
but als on the accessory sex glands has been sugges-
ted by Segal et al. (1979) in infertile hyperprolac-
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tinemic men displaying small prostates and decreased 
seminal plasma volume. Normal Leydig cell function 
has been reported by others (Carteret al., 1978; 
Franks et al., 1978) based on a normal increase of 
testosterone after stimulation with hCG in hyperpro-
lactinemic men. Although testosterone levels were 
mostly normal in our infertile patients we had the 
opportunity to study the effects of normalization of 
serum PRL levels in these hyperprolactinemic men with 
normal anterior pituitary function. Moreover, the 
effects of normalizing PRL levels on sexual distur-
bances could be studied. It has been shown that im-
potence does not improve after normalization of serum 
testosterone levels in the presence of elevated PRL 
levels (Carter et al., 1978; Luboshitzky et al., 
1979), whereas improvement of potency was noted after 
normalization of serum PRL levels in spite of contin-
ued low testosterone levels (Nagulesparen et al., 
1978). 
Sperm analyses of the 4 men in group I with macro-
adenomas were normal with the exception of decreased 
motility. One of these patients fertilized several 
weeks before admission to our hospital. Moreover 2 
patients in group II with microadenomas were able to 
father children after the time of diagnosis of their 
hyperprolactinemia without any trea·tment. These 
findings suggest that hyperprolactinemia might not be 
responsible for the sperm abnormalities in these pa-
tients. Otherwise the 4 men who were treated with 
bromocriptine and fertilized showed a small however 
significant increase of serum testosterone levels. 
The fact that basal and post-LRH levels of serum go-
nadotropins were normal in these patients and did not 
change during treatment suggests that originally not 
only the testosterone secretion was impaired but also 
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the feed-back of testosterone on LH secretion. Sperm 
analyses of men with prolactinomas may reveal azoos-
permia, oligozoospermia, normozospermia and even po-
lyzoospermia (Snyder et al., 1979). However, reports 
on fertility are very sparse. A more valid observa-
tion was done by Jequier et al. (1979) who described 
normal spermatogenesis in testicular biopsies from 
hyperprolactinemic men. Sperm qualities did not im-
prove dramatically in our patients who fertilized 
during treatment. The increase of testosterone might 
lead to an improvement of the function of the acces-
sory sex glands. HOwever, 3 of these 4 patients had 
a varicocele and underwent ligation of the sperrnati-
cal vein: this might have caused fertility (Dubin et 
al., 1975). Recently it has been shown that concep-
tion was achieved in 3 hyperprolactinernic men with 
long standing infertility during treatment with bro-
mocriptine (Laufer et al., 1981) . The increased 
sperm motility in this study underlines the possibil-
ity of improved accessory sex gland function. Thus 
it is possible that PRL has a direct effect. 
Finally, the immediate improvement of diminished 
libido in 2 infertile patients after normalization of 
serum PRL levels might suggest a direct effect of PRL 
on the brain as well. 
In conclusion our data suggest that impotence and 
loss of libido in hyperprolactinemic men are related 
to the presence of macroadenomas and high PRL levels. 
We consider that compressive effects of the tumor ac-
count for the impairment of gonadotropin secretion 
and other anterior pituitary functions. The impair-
rnent of testosterone secretion could be explained by 
a defective pituitary-gonadal axis in these patients. 
However, a direct effect of PRL on the brain, pitui-
tary and on the gonads could not be ruled out. 
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Decreased libido and testosterone levels in the lower 
normal range improved after normalization of serum 
PRL levels with bromocriptine. Fertilization during 
bromocriptine therapy also coincided very well with a 
rise in testosterone levels, without any change in 
sperm qualities. 
5. Summary 
Thirty-two men with untreated prolactinomas were 
studied. Nineteen patients (group I), referred be-
cause of headache, visual impairment or hypopituitar-
ism, had a rnacroadenoma and high PRL levels 
(982 + 294 ,ug/1; mean:!:_ S.E.M.). Impotence was pre-
sent in 12, loss of libido in 9 patients. Eleven pa-
tients of group II, comprising 13 patients out of a 
group of 598 infertile men, had a microadenoma (PRL 
levels: 42 :!:_ 8 l'g/l). 
Anterior pituitary functions, evaluated by the 
basal levels of LH, FSH, TSH and the consecutive ad-
ministration of LRH and TRH were normal in all pati-
ents of group II. Blunted responses, subnormal lev-
els of testosterone, T4 and Compound S (after metyra-
pone) were especially present in group I, which is 
considered to be due to compressive effects of the 
tumor. 
The wives of 4 of ll patients in group II treated 
with bromocriptine conceived. 2 Patients in group II 
and l in group I fathered without any treatment, in-
dicating that infertility is not necessarily a conse-
quence of hyperprolactinemia. 
Improvement of libido and increase of testosterone 
levels during bromocriptine treatment may suggest a 
direct effect of PRL. 
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CHAPTER 4 
EFFECTS OF A PRL-SECRETING TUMOR ON COPULATORY 
BEHAVIOR IN MALE RATS 
R F.A. Weber, M.P. Oorns, J.T.M. Vreeburg 
l. Introduction 
Increased levels of serum PRL in men with a pitui-
tary tumor have been associated with a loss of libido 
and potency (Carter et al., 1978; Franks et al., 
1978; Thorner & Besser, 1978). Since suppression of 
hyperprolactinemia in such patients by treatment with 
bromocriptine frequently results in restoration of 
libido and potency, it has been suggested that hyper-
prolactinemia causes a decline in libido and potency 
(Carteret al., 1978; Franks et al., 1978; Thorner 
& Besser, 1978). 
Our knowledge concerning the effects of PRL on 
mating behavior of experimental animals is fragmenta-
ry. In rats increased levels of PRL can be induced 
by grafting pituitary glands under the kidney cap-
sule. Recently, it has been demonstrated that 5 days 
after pituitary grafting several parameters of mating 
behavior in male rats were enhanced. In particular, 
significant reductions in the mount and intromission 
latencies were observed (Drago et al., 1981). In 
long-term experiments, however, mating behavior of 
such pituitary-grafted animals appeared to be sup-
pressed; the rats exhibiting increased latency to 
mount and intromission and reduced frequency of in-
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tromission (Svare et al., 1979). In addition, few 
rats with hyperprolactinemia ejaculated. Since a 
sustained increase of plasma PRL did not affect plas-
ma testosterone in these rats it may be argued that 
the effects of hyperprolactinemia on mating behavior 
are brought about by a direct action on the brain 
(Bartke, 1980). Indeed, there is strong evidence 
that PRL has a direct action on the brain; PRL en-
hances dopamine turnover in the hypothalamus (Gudel-
sky et al., 1976) and stimulates the secretion of do-
pamine into hypophysial portal blood (Cramer et al., 
1979) . 
In rats bearing transplantable PRL-producing tu-
mars, the serum concentration of PRL reaches levels 
of several ~g NIAMDD-PRL RP-1/ml (Cramer et al., 
1979; Lamberts & MacLeod, 1979; Hodson et al., 
1980; Panerai et al., 1980), levels which are much 
higher than those found in pituitary~grafted rats. 
The present study was carried out to investigate the 
mating behavior of rats bearing tumor 7315a, a tumor 
which secretes PRL and adrenocorticotropin (ACTH) 
(MacLeod et al., 1968). Since the presence of this 
tumor is accompanied in female rats by suppressed 
plasma levels of LH and FSH (Lamberts et al., 1981), 
the rats were castrated and testosterone-filled sili-
cone elastomer capsules were implanted in order to 
prevent differences in testosterone concentrations 
between tumor-bearing and control animals. In an ad-
ditional experiment, rats were adrenalectomized to 
evaluate the effects of the tumor-stimulated adrenals 
on male copulatory behavior. 
2. Materials and methods 
Male rats of the Buffalo strain were kept in a 
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room where the lights were on between 19.00 and 09.00 
h. Beginning 2 weeks after arrival in our laborato-
ry, each male was placed with a receptive female for 
at least 30 min in a plastic cage identical to his 
home cage to obtain sexual experience. These females 
were ovariectomized and made sexually receptive by 
s .c. injections of 10 fl g oestradiol benzoate 48 h 
before testing and l mg progesterone 4 h before test-
ing. This procedure was carried out twice weekly for 
3 weeks. All animals ejaculated during the last 
three tests. Subsequently, the rats were castrated 
(experiment l) and received a 1 em long silicone 
elastomer capsule (Talas, Zwolle, The Netherlands; 
outside diameter 0.1 em) filled with testosterone 
(Steraloids Inc., Wilton, New Hampshire, U.S.A.). In 
experiment 2, castrated rats were adrenalectomized. 
Adrenalectomized rats received 0.9% NaCl (w/v) solu-
tion for drinking. On the morning of day 4 after 
surgery the animals in experiment 1 were injected 
s.c. in the neck region with 0.2 rnl tumor suspen-
sion. The tumor suspension was prepared by mincing 
tumor tissues with twice its volume of 0.9% NaCl so-
lution. Test l for male copulatory behavior was car-
ried out during the afternoon of this day. 
Behavioral test 2 took place on day 7 after tumor in-
oculation, test 3 on day 14, test 4 on day 21, test 5 
on day 28 and test 6 on day 35. The rats in experi-
ment 2 were injected with tumor suspension on the 
morning of day 6 after castration and adrenalectomy. 
Test l was performed during the afternoon of this 
day. Behavioral test 2 was carried out on day 7 
after tumor inoculation, test 3 on day 14, test 4 on 
day 21, test 5 on day 28, test 6 on day 35 and test 7 
on day 42. All tests were carried out in a dimly lit 
room. 
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2.1. Behavioral testing 
After adaptation of the male to the test cage for 
5 min, a receptive female was introduced and male co-
pulatory behavior was scored. After introduction of 
the female, males were given 15 min to achieve an in-
itial intromission, and if this occurred an addition-
al 15 min to ejaculate. In the event of an ejacula-
tion, males were left in the test cage until the 
first intromission of a second copulatory series oc-
curred. The following parameters of masculine beha-
vier were scored: {a) contact latency: the time 
which elapsed between the introduction of the female 
and the first mount {with pelvic thrusting) or in-
tromission; {b) ejaculation latency: the time which 
elapsed from the first intromission until ejacula-
tion; {c) the number of mounts preceding ejacula-
tion; (d) the number of intromissions preceeding 
ejaculation; {e) post-ejaculatory interval: the 
time which elapsed between ejaculation and the first 
subsequent mount or intromission. 
For each animal, the mean value was calculated of 
a specified parameter scored in test l and 2 (normal 
plasma PRL, see below), tests 3 and 4 {moderately in-
creased plasma 
tests {markedly 
PRL) and in 
increased plasma 
the last two or three 
PRL). From these 
individual means, group means and standard errors 
were determined. When an animal did not show a spec-
ified behavior in both tests, the score obtained in 
only one test was used. 
2.2. Statistical analysis 
Results are presented as means + s.E.M. The data 
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were subjected to split-plot 2.3 design analysis of 
variance, the unweighted means solution was used be-
cause of unequal numbers of rats (Kirk, 1968) and 
P<O.OS was adopted as the level of statistical signi-
ficance. Significant interactions were tested with 
simple main effects. With significant F ratios, the 
differences between the means were tested with the 
t-ratio procedure (Kirk, 1968). 
2.3. Hormone determinations 
Four times during experiment l (Fig. 4.la) and 
three times during experiment 2 (Fig. 4.lb) blood was 
taken under ether anesthesia. Serum PRL was deter-
mined by a double-antibody radioimmunoassay using ma-
terials and protocols supplied by the NIAMDD. The 
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Fig. 4.1 Serum levels of prolactin (means± S. E .M.) in (a) castrated and 
(b) castrated and adrenalectomized tumour-bearing (solid lines) or 
control (broken lines) rats. All rats were implanted with replacement 
testosterone. Time of castration {C), adrenalectomy (A) and tumour 
inoculation (T) are shown and the arrows at the top indicate when 
the tests were carried out.* P <0. 01 compared with control rats 
(analysis of variance). 
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interassay coefficient of variation was 15%. The re-
sults are expressed in terms of NIAMDD-rat-PRL RP-1. 
Testosterone concentrations were measured by radioim-
munoassay, using the method and the antiserum first 
described by Verjans et al. (1973). The interassay 
and intra-assay coefficients of variation were 15 and 
7% respectively. 
3. Results 
3.1. Serum levels of PRL and testosterone 
Serum PRL concentrations of castrated tumor-bear-
ing rats are shown in Figure 4.la. As may be seen, 6 
days after tumor inoculation the PRL levels measured 
in the tumor-bearing rats were similar to those found 
in control animals. However, serum samples collected 
from tumor-bearing rats 20, 27 and 34 days after 
tumor inoculation contained significantly higher PRL 
levels than those found in control rats. Similar ob-
servations were made in the tumor-bearing rats after 
castration and adrenalectomy (Figure 4.lb). Twelve 
days after tumor inoculation serum PRL levels were as 
high in the control group as in the tumor-bearing 
group. The serum PRL levels measured in the tumor-
bearing rats 26 and 40 days after tumor inoculation 
were significantly higher in the tumor-bearing rats 
than in the control animals. 
After castration, testosterone was administered 
using silicone elastomer capsules filled with testos-
terone. In tumor-bearing castrated rats serum tes-
tosterone levels were similar to those found in cas-
trated control animals. Testosterone concentrations 
6 and 27 days after tumor inoculation in tumor-bear-
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ing rats were estimated to be 0.69 + 0.05 and 
0.46 + 0.11 ng/ml respectively. In control animals 
0.49 + 0.01 and 0.63 + 0.07 ng testosterone/ml was 
measured. In castrated and adrenalectomized rats on 
days 12 and 40 after tumor inoculation the testoster-
one levels were 0.79 ~ 0.06 and 0.51 ~ 0.03 ng/ml. 
In these castrated or castrated and adrenalectomized 
rats the testosterone-filled capsules induced serum 
testosterone concentrations which were much lower 
than those found recently in our laboratory in groups 
of intact (2.8 + 0.2 ng/ml) or adrenalectomized {3.2 
+ 0.5 ng/ml) rats of the same age and strain. 
3.2. Copulatory behavior 
Parameters of male copulatory behavior in castra-
ted tumor-bearing rats and control animals are shown 
in Table 4.1. Analysis of variance revealed that 
none of the parameters for male sexual behavior in 
control rats changed during the period of testing. 
However, in tumor-bearing rats a signifcant (P<O.Ol) 
increase in contact latency and ejaculation latency 
was found. In tests 3+4 the mean ejaculation latency 
of tumor-bearing rats was significantly longer than 
that found in control animals. The mean contact and 
ejaculation latencies, measured in tests 5+6 were 
significantly longer than those observed in control 
animals. Although no change in the number of intro-
missions was found, the mean number of mounts before 
ejculation increased significantly {P<O.Ol) in the 
course of the experiment. The number of mounts dis-
played by tumor-bearing rats in tests 3+4 and tests 
5+6 were significantly higher than those found in 
control rats. The rise in the number of mounts ob-
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served in tumor-bearing rats was not only reflected 
in the increased ejaculation latency but also in the 
reduced proportion of animals ejaculating in tests 
5+6, although this reduction did not reach signifi-
cance. 
After adrenalectomy and castration significant 
changes in the parameters of male copulatory behavior 
did not develop in either the tumor-bearing rats or 
the controls (Table 4.1). 
4. Discussion 
In the present study an increase in serum PRL lev-
els was induced by the transplantable tumor 7315a. 
Since the serum levels of PRL measured within 12 days 
after tumor inoculation were not significantly ra-
ised, the first and second tests for male copulatory 
behavior were carried out when serum PRL levels were 
normal. However, serum PRL increased sharply during 
the course of the experiment. Two days before test 5 
serum PRL concentrations of more than 2000 ng/ml in 
castrated and more than 1000 ng/ml in castrated and 
adrenalectomized rats were found. At the time of the 
last tests, more than 4000 ng PRL/ml serum was pre-
sent. The extremely high levels of PRL in rats bear-
ing tumor 7315a have also been found by other inves-
tigators (Cramer et al., 1979; Lamberts & MacLeod, 
1979; Panerai et al., 1980). 
The data we have presented have shown that in cas-
trated rats implanted with testosterone-filled cap-
sules, tumor 7315a has a markedly inhibitory effect 
on male copulatory behavior. In the course of the 
experiment tumor-bearing rats displayed a growing 
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TABLE 4.1 Copulatory behavior of castrated and of castrated and adrenalectomized rats 
after administration of testosterone and tumor inoculation. 
test group rats no. of no. of contact ejaculatory post-
ejaculating mounts intromissions latency latency ejaculatory 
twice t before before interval 
ejaculation ejaculation (s) (s) (s) 
castrated rats 
1+2 tumor 7/7 5. 2 + 1.7 14.7 + 2.2 21.7 + 11.2 287 + 43 218 + 9 
control 6/6 5.8 + 1.8 13.8 + 1.0 14.8 + 5.1 327 + 47 247 :': 15 
3+4 tumor 7/7 24.1 + 5.7x 14.7 + 1.5 41.6 + 25.0 493 + 72x 230 + 11 
control 6/6 6.5 + 0.9 12.8 + 0.8 15.7 + 8.9 286 + 30 242 + 10 
5+6 tumor 4/7 52.3 + 12.2xxll.7 + 1.1 325.1 + 97xx 836 + 130xx273 + 34 
- - - -
control 6/6 7.5 + 1.1 14.5 + 1.3 20.5 + 14.9 296 + 29 212 + 6 
castrated and adrenalectomized rats 
1+2 tumor 5/7 18.9 + 5.0 11.4 + 0.8 82 + 38 613 + 125 340 :': 16 
control 6/7 15.8 + 3.1 11.0 + 0.7 68 + 15 516 + 73 325 :': 10 
3+4 tumor 5/7 17.9 + 5.9 9.6 + 0.7 47 + 16 512 :': 113 366 + 36 
control 5/7 8.4 + 2.2 10.1 + 0.8 187 + 104 422 + 53 403 :': 62 
5+6+7 tumor 5/7 29.0 + 5.7 11.1 + 0.9 84 :': 20 892 + 153 378 + 37 
control 7/7 18.4 + 3.4 9.5 + 0.6 175 + 37 576 + 82 342 + 61 
values are means + S.E.M. 
x P<O.OS,xx P<O.Ol compared with control rats (analysis of variance) 
'"' t all animals ejaculated at least once __, 
number of mounts before ejaculation. The number of 
intromissions leading to ejaculation, however, rema-
ined the same. The increase in ejaculation latency 
seems therefore to be the consequence of a relative 
inability to intromit. Although (even during the 
last tests) tumor-bearing animals were sexually very 
acti.ve, mounting or intromitting as frequently as 
control rats, their contact latency was significantly 
increased. Our findings are similar in part to those 
found by Svare et al., (1979). 
studying copulatory behavior 
These investigators, 
of pituitary-grafted 
male rats, also found increase mount and ejaculation 
latencies. In contrast to our findings, they report-
ed a decrease in the proportion of rats which ejacu-
lated and a reduction in the number of mounts and in-
tromissions. 
The differences in mating behavior between 
tumor-bearing rats and control rats were no longer 
present when the adrenals were removed before tumor 
inoculation. This observation suggests that secreto-
ry products of the adrenal are involved in the sup-
pression of mating behavior. Tumor 7315a secretes 
both PRL and ACTH (MacLeod et al., 1968) resulting in 
adrenals which at autopsy were five times heavier in 
the tumor-bearing rats than in the control rats (data 
shown in Chapter 5). It is unclear therefore whether 
PRL, ACTH or a combination of both hormones are need-
ed to cause the inhibitory action of the adrenal. 
An alternative explanation for the abscence of an 
effect of PRL on mating behavior after adrenalectomy 
might be that this hormone exerts its inhibitory ef-
fect only in the presence of corticosteroids. 
Doherty et al., (1980) recently studied copulatory 
behavior of pituitary-grafted adrenalectomized rats. 
They reported that pituitary grafts prolonged the la-
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tencies to mount and intromit both in intact and 
adrenalectomized rats and concluded that the suppres-
sion of copulatory behavior is not due to stimulation 
of the adrenal activity by hyperprolactinemia. The 
discrepancy between our results and those of Doherty 
et al. (1980) might be caused by the fact that the 
latter investigators injected the adrenalectomized 
rats with corticosterone. An interaction between PRL 
and corticosteroids is well known as a cause of milk 
production and was confirmed in the present experi-
ments. In tumor-bearing male rats mammary glands 
full of milk were found, whereas in adrenalectomized 
tumor-bearing animals the glands were empty. In ad-
dition, a synergism between PRL and the adrenals 
seems to be involved in the suppression of LH during 
hyperprolactinemia (Greely & Kizer, 1979). 
Hyperprolactinemia in men is associated both with 
hypogonadism and impotence (Carter et al., 1978; 
Franks et al., 1979; Thorner & Besser, 1978; Kirby 
et al., 1979). Therefore, the impotence might be re-
lated to increased serum PRL in combination with low 
testosterone. We therefore supplied the rats after 
castration with relatively small testosterone-filled 
capsules. Testosterone concentrations were similar 
in tumor-bearing and control rats 1 showing that PRL 
has no significant influence on the metabolic clear-
ance rate of testosterone. 
It has been shown recently 
that besides PRL and ACTH, 
(Panerai et al., 1980) 
tumor 7315a secretes 
p-endorphin. This opioid peptide has been found to 
suppress copulatory behavior in male rats after in-
traventricular injection 
Mcintosh et al., 1980). 
(Meyerson et al., 1977; 
Inhibition of male copulate-
ry behavior has also been reported after systemic ad-
ministration of 4-10 ACTH to castrated rats which 
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were injected with testosterone propionate (Bohus et 
al., 1975). Since, if anything, these peptides inhi-
bit male copulatory behavior, the conclusion that PRL 
does not suppress copulatory behavior in adrenalec-
tomized rats is valid. Whether this is the case in 
adrenalectomized rats injected with corticosterone 
will be investigated. 
5. Summary 
The effect of the transplantable PRL- and ACTH-se-
creting tumor 7315a on male copulatory behavior was 
investigated. Castrated tumor-bearing rats implanted 
with testosterone-filled capsules exhibited signifi-
cantly longer latencies to first mount or intromis-
sion and to ejaculation than castrated and substitut-
ed control animals. In contrast to the number of in-
trornissions, the number of mounts before ejaculation 
of the tumor-bearing rats was considerably increased. 
However, when castration was carried out in addition 
to adrenalectomy, the differences in copulatory beha-
vior between tumor-bearing rats and control rats were 
no longer present. During the last tests for copula-
tory behavior the tumor-bearing rats had serum PRL 
concentrations of more than 4000 ng/ml while control 
rats had less than 100 ng/ml. Plasma testosterone 
levels produced by silicone elastomer capsules were 
neither affected by the presence of the tumor nor by 
adrenalectomy. It was concluded that hyperprolacti-
nemia does not suppress the copulatory behavior of 
adrenalectomized rats. 
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CHAPTER 5 
EFFECTS OF A PRL- AND ACTH-SECRETING TUMOR ON GONA-
DOTROPIN LEVELS AND ACCESSORY SEX ORGAN WEIGHTS 
IN ADULT MALE RATS: A POSSIBLE ROLE OF THE ADRENALS 
R.F.A. Weber, M.P. Ooms and J.T.M. Vreeburg 
l. Introduction 
It is well established that chronically elevated 
plasma PRL levels induced by pituitary grafts sup-
press basal 
male rats 
gonadotropin 
(Bartke et 
concentrations in intact 
al., 1977; Celotti et al., 
1979; McNeilly et al., 1978; Greeley & Kizer, 
1979). Since plasma testosterone levels in these an-
imals were not affected (Bartke et al., 1977; 
McNeilly et al., 1978), it seems reasonable to con-
clude that high levels of PRL exert an inhibitory ef-
fect on gonadotropin secretion. This inhibitory ef-
fect of PRL on gonadotropin secretion in intact male 
rats is even more pronounced after the implantation 
of a PRL-producing tumor (MtTWlS); the extremely 
high plasma PRL levels induced by this tumor are ac-
companied by a strong suppression not only of serum 
LH but also of serum testosterone (Hodson et al., 
1980). Besides the suppression of basal gonadotropin 
secretion in intact animals, PRL can also inhibit the 
rise of plasma gonadotropins after gonadectomy (Gu-
delsky et al., 1976; Winters & Loriaux, 1978; 
McNeilly et al., 1980). As in intact animals, the 
inhibition of gonadotropin secretion in gonadectom-
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ized rats treated with PRL-producing tumors (Grandi-
son et al., 1977; Hodson et al., 1980) was greater 
than that seen after grafting pituitaries under the 
kidney capsule. This difference might be explained 
by the higher PRL levels found in the presence of the 
tumor. Recently, it has been suggested that the 
adrenals are involved in the modulatory role of PRL 
on the secretion of LH in pituitary-grafted male rats 
(Greeley & Kizer, 1979; Svare et al., 1979). 
However, other investigators using pituitary grafts 
(McNeilly et al., 1980), the PRL- and GH-secreting 
tumor MtTW15 (Hodson et al., 1980), or the PRL- and 
ACTH-secreting tumor 7315a (Lamberts et al., 1981) 
found that the serum gonadotropin levels were as much 
reduced in the presence as in the absence of adre-
nals. The present study was carried out to investi-
gate the possible effect of the adrenal on the regu-
lation of gonadotropin secretion in the presence of 
the PRL- and ACTH-secreting tumor 7315a. 
2. Materials and methods 
2.1. Animals 
Adult male rats of the Buffalo or the Buffalo x 
Wag/Rij strain were used. The animals were kept 
under conditions of controlled lighting (14 h of 
light and 10 h of darkness) and constant temperature 
(20-22°C) . Pellet food (Hope Farms Standard Labora-
tory Diet) and tap water were provided ad libitum. 
Adrenalectomized animals received saline for drink-
ing. Hyperprolactinemia was induced by the s.c. 
injection of 0.2 ml 7315a tumor tissue minced in sa-
line (w/v, 1:2). Blood samples were collected by or-
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bital sinus puncture under ether anesthesia. At the 
end of the experiments, the rats were killed by de-
capitation, and trunk blood was collected. Testes, 
seminal vesicles, prostates, and adrenals (if pre-
sent) were then removed and weighed. 
EXP. l 
On day 0, intact Buffalo x Wag/Rij rats were in-
jected with a suspension of tumor 7315a. Untreated 
animals served as controls. On day 14, blood was 
collected. On day 34, the animals were decapitated, 
and trunk blood was collected. 
EXP. 2 
A group of Buffalo x Wag/Rij rats was gonadectom-
ized and treated (s.c.) with a 1-crn long Silastic 
capsule (od, 0.1 ern) filled with testosterone. In 
Exp. 2, 3, and 4, the day of surgery was day 0. On 
day 4, half of the animals were injected with tumor 
suspension. Subsequently (days 10 and 24), blood was 
taken from the orbital plexus. On day 38, trunk 
blood was collected. 
EXP. 3 
After gonadectomy and adrenalectomy, a group of 
Buffalo rats received 1-cm long Silastic capsules 
filled with testosterone. On day 7, the tumor sus-
pension was injected into half of the animals. Blood 
was taken by puncturing the orbital plexus on days 19 
and 33 and by decapitation on day 47. 
EXP. 4 
Adrenalectomized Buffalo rats and sham-operated 
control animals were injected with tumor suspension 
on day 7. On days 13, 26, and 39, blood was taken. 
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2.2. Hormone assays 
Serum levels of LH and FSH were determined using 
the antisera and procedure·s developed in our labora-
tory (We1schen et a1., 1975). Serum levels of PRL 
were measured using materials and protocols supplied 
by the NIAMDD Rat Pituitary Hormone Distribution Pro-
gram. Concentrations of PRL, LH and FSH are ex-
pressed in terms of the standard NIAMDD reference 
preparations (NIAMDD-LH RP-1, NIAMDD-FSH RP-1, and 
NIAMDD-PRL RP-1). The inter assay coefficients of 
variation were 9% for FSH, 11% for LH, and 15% for 
PRL. The amounts of hormone that reduced binding of 
labeled hormone to 90% of that occurring in the ab-
sence of unlabeled hormone were 6 ng FSH, 
and 0.4 ng PRL. 
2 ng LH, 
Serum levels of progesterone were determined by 
RIA using the method and antisera described previous-
ly (de Jong et al., 1974). Serum levels of testes-
terone were estimated using the method and antisera 
first described by Verjans et al. (1973). The in-
terassay coefficients of variation were 13% for the 
progesterone assays and 15% for the testosterone as-
says. The percentage binding of radioactive steroid 
in the presence of 15 pg progesterone or testosterone 
in the corresponding assays was significantly 
(p<O.Ol) different from the control value. 
2.3. Statistical analysis 
The data were examined by analysis of variance, 
using the split plot design (Kirk, 1968); P<0.05 was 
adopted as the level of statistical significance. 
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TABLE 5.1 Body and organ weights of experimental and control rats. 
no. of BW testis epididymis seminal prostate adrenal 
rats wt wt vesicle wt 
(g) (mg)a {mg)a (mg)a (mg) {mg)a 
Exp l 
intact + tumor 7 274 + 39b 2928 + Slb 651 + 25b 146 + l3b 132 + l3b 267 + 58b 
-
intact 7 336 
.:!: ll 3527 + 38 997 + 15 339 + 10 352 .:!: 16 40 + 2 
Exp 2 
gonadex + tumor 8 345 
.:!: lOb 403 + l8c 148 + 4b 199 .:!: l4b 296 + l3b 
gonad ex 6 408 + 4 481 + 12 335 + 3 341 + 21 50 + 2 
Exp 3 
adrenex + gonadex + tumor 7 348 
.:!: 6 440 + 12 260 + 12 258 + 18 
adrenex + gonadex 7 351 + 7 457 + ll 241 + 15 240 + 17 
Exp 4 
adrenex + tumor 6 328 + llc 2891 +· 39b 767 + l5b 327 + 28b 365 + 22b 
intact + tumor 6 294 + 5 2545 + 42 589 + 20 126 + 8 145 + 8 294 + 7 
Values shown are the mean + S.E.M. Adrenex, adrenalectomized; gonadex, gonadectomized and 
treated S.C. with a Silastic capsule filled with testosterone. Tumor inoculations were 
carried out 32-40 days before autopsy. 
a 
sum of the two organs 
b P<0.01 vs control 
0 c P<O.OS vs control 'D 
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Fig. 5.1 Serum levels (mean±SE) of LH, FSH, testosterone, and PRL in 
intact tumor-bearing rats {e--e) and intact control rats (o-o) . Tumor ino-
culation was carried out on day 0. **,Significant differences between 
tumor-bearing rats and control rats (P <0.01). 
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Significant interactions were tested with simple main 
effects. Means and S.E.M. values of body and organ 
weights were compared for significant differences by 
Student's t-test. 
3. Results 
EXP. 1: effects of tumor growth in intact male rats. 
Serum levels (mean ~ S.E.M) of PRL, LH, 
testosterone are shown in Figure 5.1. 
FSH, and 
By day 14 
after tumor inoculation, PRL levels of tumor-bearing 
rats were as low as those in controls. Serum levels 
of LH, FSH, and testosterone determined in the same 
samples were not different in intact and 
tumor-bearing rats. However, the serum PRL concen-
trations 3 weeks later were significantly hi~her in 
tumor-bearing rats (2160 + 203 ng/rnl) than in con-
trols (108 ~ 19 ng/rnl). Concentrations of LH, FSH, 
and testosterone were significantly lower in 
tumor-bearing animals than in controls. Mean serum 
concentrations of FSH, LH and testosterone in 
tumor-bearing rats were 2.0, 
than those found in control 
2.5, and 6.0 times lower 
animals. Weights of 
testes, epididymides, seminal vesicles, and prostates 
were all significantly lower in the tumor-bearing an-
imals than in controls (Table 5.1). In contrast, 
tumor-bearing rats had a significantly increased 
adrenal weight compared with that of the control ani-
mals. 
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Fig. 5.2 Serum levels (mean ±SE) of LH, FSH, testosterone, and PRL in 
tumor-bearing, gonadectomized rats ( ...... J and gonadectomized control rats 
(o--o}. The gonadectomized rats were treated with small testosterone-filled 
capsules. The animals were gonadectomized on day 0. Tumor inoculation 
was carried out on day 4. **, Significant differences between tumor-bea-
ring rats and control rats ( P <0. 01). 
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EXP. 2: effects of tumor growth in gonadectomized, 
testosterone-treated male rats. 
Six days after tumor inoculation, there were no 
significant differences in the serum levels of PRL, 
LH, FSH, and testosterone between control and 
tumor-bearing rats (Figure 5.2). HOwever, on day 20 
after tumor inoculation, the PRL level in 
tumor-bearing rats appeared to be significantly 
higher than that in control animals. Despite the ab-
sence of significant differences in testosterone con-
centrations in these serum samples, the concentrati-
ons of LH and FSH were significantly lower in tumor-
bearing than in control rats. The observations made 
on day 34 after tumor inoculation were similar to 
those made on day 20 (Fig. 5.2). The weights of the 
epididymides, seminal vesicles, and prostates were 
significantly lower in tumor-bearing rats than in 
controls (Table 5.1), although the testosterone lev-
els were not significantly different between groups. 
In a separate group of rats treated as described 
above, serum progresterone levels 4 weeks after tumor 
inoculation were significantly (P<O.Ol) higher in 
tumor-bearing rats (25.1 ~ 4.1 ng/ml) than in control 
animals (0. 6 + 0.1 ng/ml). 
EXP. 3: effects of tumor growth in adrenalectomized, 
gonadectomized, testosterone-treated male 
rats 
During the course of the experiment, serum PRL 
levels increased considerably in tumor-bearing rats~ 
no significant changes in PRL occurred in controls 
(Fig. 50 3) 0 
Notwithstanding the large difference in serum PRL 
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Fig. 5.3 Serum levels (mean ±SE) of LH, FSH, testosterone, and PRL in 
tumor-bearing, adrenalectomized and gonadectomized rats (...._..) and in 
adrenalectomized and gonadectomized control rats (o--o). The gonadecto·· 
mized animals were treated with small testosterone-filled capsules. Sur-
gery was carried out on day 0. Tumor inoculation was performed on day 
7. Significant differences between tumor-bearing rats and control rats 
are indicated(**, P <0.01;*, P<O.OS). 
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levels in tumor-bearing and control rats, the concen-
trations of LH and FSH were not significantly differ-
ent between the two groups on day 42 after tumor ino-
culation. On day 27 after tumor inoculation, the 
tumor-bearing rats had a small but significant reduc-
tion in the serum LH level. On this day, however, 
the serum FSH concentration was as high in 
tumor-bearing rats as in controls. Testosterone con-
centrations were not significantly different between 
control and tumor-bearing rats. Serum progesterone 
concentrations were low in both tumor-bearing rats 
(0.6 ~ 0.1 ng/ml) and control rats (0.9 ~ 0.6 ng/ml). 
Furthermore, the weights of the epididymides, seminal 
vesicles, and prostates from tumor-bearing rats did 
not differ from those in controls (Table 5.1). 
EXP. 4: effects of adrenalectomy in tumor-bearing 
male rats. 
Six days after tumor inoculation, serum levels of 
PRL approximated those in 
experiments (Fig. 5.4). 
control animals of previous 
On days 19 and 32 ~fter 
tumor inoculation, an increase in serum PRL was found 
in both intact and adrenalectomized rats. 
Exp. 1, serum levels of LH and FSH decreased 
cantly (P<0.01) in tumor-bearing intact rats 
As in 
signifi-
during 
the course of the experiment. In contrast, in adre-
nalectomized tumor-bearing animals, LH and FSH con-
centrations remained unchanged. Although serum tes-
tosterone concentrations decreased significantly in 
both intact (P<0.01) and adrenalectomized (P<0.05) 
rats, the testosterone levels on days 19 and 32 were 
significantly lower in intact animals than in adrena-
lectomized rats. At autopsy, the weights of testes, 
epididymides, seminal vesicles, and prostates were 
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Fig. 5.4 Serum levels {mean ±SE) of LH, FSH, testosterone, and PRL in 
tumor~bearing, adrenalectomized rats ( ...... ) and tumor-bearing control rats 
(0--0). Adrenalectomy was performed on day 0. Tumor inoculation was 
carried out on day 7. Significant differences between tumor-bearing rats 
and control rats are indicated(** .. P <0.01;*, P <0.05). 
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all significantly lower in intact tumor-bearing rats 
than in control rats (Table 5.1). 
4. Discussion 
In the present study, a major increase in the con-
centration of serum PRL in male rats was induced by 
the PRL- and ACTH-secreting tumor 7315a. At the end 
of the experiments, 5-6 weeks after tumor inocula-
tion, PRL levels of several micrograms per ml were 
found. Similar high values of PRL in rats bearing 
tumor 7315a have also been found by other investiga-
tors (Cramer et al., 1979; Panerai et al., 1980; 
Lamberts et al., 1981). Since an association of hy-
perprolactinemia with low levels of LH and FSH is 
well established in intact male rats (Bartke et al., 
1977; Celotti et al., 1978; McNeilly et al., 1978; 
Greeley & Kizer, 1979; Hodson et al., 1980), we were 
not surprised to find greatly reduced LH and FSH lev-
els in intact tumor-bearing rats. However, in con-
trast to the results obtained in studies with animals 
grafted with normal pituitary tissue (Bartke et al., 
1977; McNeilly et al., 1978), a decrease in both 
testosterone and weights of testes and accessory sex 
organs was found in the present and earlier investi-
gations (Fang et al., 1974; Hodson et al., 1980) in 
which hyperprolactinemia was induced by PRL-producing 
tumors. 
The combination of low serum LH and FSH levels 
with a low serum testosterone level was also found in 
our tumor-bearing, gonadectomized male rats. After 
gonadectomy, these animals received a testosterone-
filled capsule which was too small to inhibit the 
postcastration rise in gonadotropins. Nevertheless, 
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when the tumor produced an increase in PRL, a further 
rise of serum LH and FSH was prevented. In fact, the 
elevated levels of serum gonadotropins were markedly 
reduced. Unexpectedly, the suppressive effects of 
the tumor on gonadotropin levels were completely ab-
sent in adrenalectomized animals. Even in the pres-
ence of serum PRL levels of about 5 ,u g/ml, the LH and 
FSH concentrations in gonadectomized, adrenalectom-
ized, tumor-bearing rats were not different from 
those in gonadectomized, adrenalectomized rats. A 
similar observation was made in noncastrated adrena-
lectomized rats, in which a large increase in serum 
PRL induced by the tumor did not affect serum LH and 
FSH levels. 
Our findings that high serum levels of PRL do not 
influence circulating LH and FSH in adrenalectomized 
rats are at variance with observations made by other 
investigators. Using the PRL- and GH-producing tumor 
MtTWl5, Hodson et al. (1980) observed that the post-
castration rise in serum LH was as much reduced in 
adrenalectomized, gonadectomized, tumor-bearing rats 
as in gonadectomized rats. Their data suggest that, 
regardless of the presence of the adrenals, high lev-
els of PRL inhibit LH release. In addition, hyper-
prolactinemia induced by pituitary grafts (McNeilly 
et al., 1980) has been found to suppress gonadotropin 
levels in adrenalectomized rats. In the latter study 
however, the presence of the testes was required for 
pituitary grafts to exert an inhibitory effect on LH 
and FSH. The discrepancies between these findings 
(Hodson et al., 1980; McNeilly et al., 1980) and 
ours demonstrate that results obtained with tran-
splants of normal pituitary tissue or tumor MtTWlS 
are different from those with tumor 7315a. Despite 
differences in the secretory activity of the various 
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types of PRL-producing transplants, it is difficult 
to explain why hyperprolactinemia induced in adrena-
lectomized male rats by pituitary grafts (McNeilly et 
al., 1980) or by pituitary tumor MtTWlS (Hodson et 
al., 1980) suppresses gonadotropin secretion while 
hyperprolactinemia elicited in similar animals by 
tumor 7315a does not. 
Tumor 7315a secretes both PRL and ACTH (MacLeod et 
al., 1968). This resulted in adrenals which at au-
topsy were more than 6 times heavier than those in 
controls. It seems clear from the present data that 
secretory products of the tumor-stimulated adrenals 
are involved in the suppression of LH and FSH. This 
gonadotropin suppression might be due to ACTH, since 
the administration of ACTH to intact male rats can 
cause a reduction in testicular and accessory sex 
organ weights (Asling et al., 1951). Nevertheless, 
in the presence of the adrenals, PRL may a·lso be in-
volved in the suppression of LH and FSH. In gonadec-
tomized, tumor-bearing rats, we measured high serum 
concentrations of progesterone, which were probably 
induced by stimulation of the adrenals by ACTH (Reske 
et al., 1969; Feder et al., 1971) or by ACTH plus 
PRL (Piva et al., 1973). Although progesterone alone 
does not affect gonadotropin levels in the rat (Cali-
garis et al., 1971; Nuti et al., 1977), there is ev-
idence that this hormone together with PRL might have 
some inhibitory effect on LH and FSH. It has been 
found that. the LH response to LRH is significantly 
depressed in hyperprolactinemic intact female rats 
(Vasquez et al, 1980). This phenomenon was attribut-
ed to the action of progesterone, since it was also 
found in hypeprolactinemic ovariectomized rats when 
progesterone was administered. Furthermore, Lamberts 
et al. (1981) reported that LH and FSH levels were 
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suppressed in adrenalectomized female rats bearing 
tumor 7315a. This observation is difficult to recon-
cile with our finding that FSH and LH were not inhi-
bited in adrenalectomized males, unless we assume 
that high levels of PRL and progesterone secreted by 
the ovaries inhibited LH and FSH in females. Anal-
ternative possibility is that tumor 7315a suppresses 
serum gonadtropin levels in female rats without medi-
ation of the secretory products of adrenals and ovar-
ies. 
In intact tumor-bearing rats, the weights of the 
prostate, seminal vesicles, and epididymides were 
markedly reduced compared to the values in controls. 
In part, this reduction must be the consequence of 
the decreased serum tetosterone concentration. 
fbwever, the presence of the tumor also caused a re-
duction of sex accessory organ weights in gonadectom-
ized, testosterone-treated animals in which testos-
terone levels were not different from those in the 
non-tumor-bearing gonadectomized rats. 
hibitory effects of the tumor on organ 
completely absent in adrenalectomized 
Since the in-
weights were 
animals, it 
seems likely that compounds secreted by the adrenals 
reduced the androgenic action of testosterone. One 
possible antiandrogenic substance is progesterone 
(Dorfman, 1967). 
5. Summary 
The presence of the transplantable PRL- and ACTH-
secreting tumor 7315a in intact male rats resulted in 
very high serum PRL levels, decreased levels of LH 
and FSH, and reduced weights of testes and accessory 
sex organs. In gonadectomized rats bearing a small 
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testosterone-filled capsule, the tumor inhibited the 
postcastration rise in gonadotropins and reduced the 
weights of the prostate and seminal vesicles. 
However, after adrenalectomy of intact and gonadec-
tomized male rats bearing a small testosterone filled 
capsule, inhibitory effects of the tumor on serum go-
nadotropin levels or on reproductive organ weights 
were totally absent. These results show that in 
adrenalectomized rats, hyperprolactinemia in itself 
does not affect gonadotropin secretion and the andro-
genic action of testosterone. Rather, the tumor 
might exert a gonadotropin inhibitory action through 
elevated levels of PRL combined with progesterone, 
which is secreted by the ACTH-stimulated adrenal. 
121 
6. References 
Asling, C.W., Reinhardt, W.O. & C.H. Li. Effects of adre-
nocorticotropic hormone on body growth, visceral propor-
tions, and white blood cell counts of normal and hypo-
physectomized male rats. Endocrinology 1951, 48, 534-
547. 
Bartke, A-, Smith, M S , Michael, S.D I Peron, F.G. & S. 
Dalterio. Effects of experimentally-induced chronic hy-
perprolactinemia on testosterone and gonadotropin levels 
in male rats and mice. Endocrinology 1977, 100, 182-
186. 
Caligaris, L., Astrada, J.J. & s. Taleisnik. Biphasic ef-
fect of progesterone on the release of gonadotropin in 
rats. Endocrinology 1971, 89, 331-337. 
Celotti, F., Massa, 
on LH release 
26, 41-49. 
R. & L. Martini. Effect of prolactin 
in male rats- Neuroendocrinology 1978, 
Cramer, 0 M , Parker, C.R. & J.C. Porter. Secretion of do-
pamine into hypophysial portal blood by rats bearing 
prolactin-secreting tQmors or ectopic pituitary glands. 
Endocrinology 1979, 105, 636-640. 
Dorfman, R.I. The antiestrogenic and antiandrogenic activ-
ities of progesterone in the defense of a normal fetus. 
Anat. Rec. 1967, 157, 547-557. 
Fang, v.s., Refetoff, S. & R-L. Rosenfield. Hypogonadism 
induced by a transplantable, prolactin-producing tumor 
in male rats: hormonal and morphological studies. 
Endocrinology 1974, 95, 991-998. 
Feder, H. H., Brown-Grant, K. & C- S. Corker. Pre-ovulatory 
progesterone, the adrenal cortex and the "critical peri-
od'' for luteinizing hormone release in rats. 
crinol. 1971, 50, 29-39. 
J. En do-
Grandison, L., Hodson, C., Chen, H.T., Advis, J., Simpkins, 
J. & J. Meites Inhibition by prolactin of post-cas-
tration rise in LH. Neuroendocrinology 1977, 23, 312-
322. 
122 
Greeley, G.H. & J.s. Kizer. Evidence for adrenal involve-
ment in the modulatory role of prolactin in luteinizing 
hormone secretion in the male rat. Endocrinology 1979, 
104, 948-953 
Gudelsky, G.A., Simpkins, J., Mueller, G.P., Meites, J. & 
K.E. Moore. Selective actions of prolactin on catechol-
amine turnover in the hypothalamus and on serum LH and 
FSH. Neuroendocrinology 1976, 22, 206-215 
Hodson, C.A., Simpkins, J.W., Pass, K.A., Aylsworth, C.F. I 
Steger, R.W. & J. Meites. Effects of a prolactin-se-
creting pituitary tumor on hypothalamic, gonadotropic 
and testicular function in male rats. Neuroendocrine-
logy 1980, 30, 7-10. 
Jong, F"H. de, Baird, D T. & H J, van der Molen. Ovarian 
secretion rates of oestrogens, androgens and progester-
one in normal women and in women with persistent ovarian 
follicles. Acta Endocrinol. 1974, 77, 575-587. 
Kirk, R.E. Experimental design: procedures for the behavi-
oral Sciences. Brooks/Cole, 1968. Belmont, California. 
Lamberts, S.W.J., Zuiderwijk, J.M , Bans, E.G., Uitterlin-
den, P. & F.H. de Jong. Gonadotropin secretion in rats 
bearing a prolactin-secreting pituitary tumor: effects 
of naloxone administration. Fertil. Steril. 1981, 35, 
557-562. 
MacLeod, R.M., DeWitt, G.W. & M.C. Smith. Suppression of 
pituitary gland hormone content by pituitary tumor hor-
manes. Endocrinology 1968, 82, 889-894. 
McNeilly, A.S., Sharpe, R.M., Davidson, D W. & H.M. Fraser. 
Inhibition of gonadotrophin secretion by induced hyper-
prolactinaemia in the male rat. 
79, 59-68. 
J. Endocrine!. 1978, 
McNeilly, A.S., Sharpe, R.M. & H.M. Fraser. Effect of 
adrenalectomy or castration on the inhibition of gonad-
trophin secretion induced by hyperprolactinaemia in the 
adult male rat. J. Endocrinol. 1980, 85, 83-92. 
123 
Nuti, K.M. & H.J. Karavolas. Effect of progesterone and 
its Sa-reduced metabolites on gonadotropin levels in es-
trogen-primed ovariectomized rats. 
100, 777-781. 
Endocrinology 1977, 
Panerai, A.E., Sawynok, J., LaBella, F.S. & H.G. Friesen. 
Prolonged hyperprolactinemia influences /)-endorphin and 
met-enkephalin in the brain. Endocrinology 1980, 106, 
1804-1808. 
Piva, F., Gagliano, p., Motta, M. & L. Martini. Adrenal 
progesterone: factors controlling its secretion. 
crino1ogy 1973, 93, 1178-1184. 
En do-
Resko, J.A. Endocrine control of adrenal progesterone se-
cretion in the ovariectomized rat. Science 1969, 164, 
70-71 
Svare, B., Bartke, A., Doherty, P.' Mason, I., Michael, 
S.D. & M.S. Smith. Hyperprolactinemia suppresses copu-
latory behavior in male rats and mice. Biol. Reprod. 
1979, 21, 529-535. 
vasquez, J.M., Ellegood, J.O., Nazian, S.J. & V.B. Mahesh. 
Effect of hyperprolactinemia on pituitary sensitivity to 
luteinizing hormone-releasing hormone following manipu-
lation of sex steroids. Peril. Steril. 1980, 33, 543-
549. 
Verjans, H.L., Cooke, B.A., de Jonq, F.H., de Jonq, C.M.M. 
& H.J. van der Molen. Evaluation of a radioimmunoassay 
for testosterone estimation. J. Steroid. Biochem. 1973, 
4, 665-676. 
Welschen, R., Osman, P., Dullaart, J,, de Greef, W.J., Ui-
lenbroek, J.Th.J. & F.H. de Jong. Levels of follicle 
stimulating hormone, luteinizing hormone, oestradiol-
17 f~ and progestesterone, and follicular growth in the 
pseudopregnant rat. J. Endocrine!. 1975, 64, 37-47. 
Winters, S.J. & D.L. Loriaux. Suppression of plasma lu-
teinizing hormone by prolactin in the male rat. Endo-
crinology 1978, 102, 864-868. 
124 
NEUROENDOCRI:-.'OLOGY 1983, 36, 205~210 
CHAPTER 6 
LRH LEVELS AND DOPAMINE LEVELS IN HYPOPHYSIAL 
STALK PLASMA AND THEIR RELATIONSHIP TO PLASMA 
GONADOTROPINS AND PRL LEVELS IN MALE RATS BEARING 
A PRL- AND ACTH-SECRETING PITUITARY TUMOR 
R.F.A. Weber, W.J. de Greef, J. de Koning, 
J.T.M. Vreeburg 
1. Introduction 
During conditions of hyperprolactinemia plasma 
levels of LH and FSH are suppressed in female rats 
(Bartke et al., 1977; McNeilly et al., 1978; Lam-
berts et al., 1981). This phenomenon could be due to 
a direct effect of PRL on the gonadotropin-secreting 
cells since a blunted response of gonadotropins dur-
ing stimulation with LRH has been observed in hyper-
prolactinemic rats (Winterset al., 1978; Vasquez et 
al., 1980). It is also possible that the inhibitory 
effect of PRL on the levels of gonadotropins could be 
mediated through the hypothalamus, perhaps resulting 
in a decreased release of LRH into the hypophysial 
portal vessels (Grandison et al., 1977; Hodson et 
al., 1981) . 
The secretion of PRL from the adenohypophysis in 
situ is inhibited after implantation of PRL into the 
hypothalamus or when plasma levels of PRL are elevat-
ed by ectopic pituitary grafts or PRL-secreting tu-
mors (MacLeod, 1968; Mena et al., 1968; 
Voogt & Meites, 1971; Dang & Voogt, 1977; de Greef 
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& Zeilrnaker, 1978; de Greef et al., 1980). This ne-
gative feedback action of PRL is probably exerted 
through altered hypothalamic release of neurohormones 
involved in the release of adenohypophysial PRL 
(Maltz et al., 1978; Voogt & Carr, 1974). Indeed, 
increased hypophysial stalk plasma levels of dopam-
ine, a physiological PRL release-inhibiting factor 
secreted by the hypothalamus into the portal 
blood (MacLeod, 1976; Gibbs & Neill, 1978; Gibbs et 
al., 1979; de Greef & Neill, 1979; Neill et al., 
1979), were observed in rats bearing a PRL-secreting 
tumor (Cramer et al, 1979; Gudelsky & Porter, 1980). 
It has been suggested that hypothalamic dopamine is 
involved in the regulation of hypothalamic LRH secre-
tion (Hokfelt et al., 1972, McNeilly et al., 1978). 
Thus, the inhibitory effects of PRL on the secretion 
of gonadotropins may be caused by an effect on hypo-
thalamic dopamine turnover (Gudelsky et al., 1976). 
It was the aim of the present study to investigate 
the effects of hyperprolactinemia on the concentra-
tions of LRH and dopamine in hypophysial stalk plasma 
of male rats. Hyperprolactinemia was induced by the 
transplantable 7315a tumor which secretes PRL and 
ACTH (MacLeod et al., 1968). Since it has been re-
ported that in the male rat the adrenal glands are 
required for the effect of this tumor on the secre-
tion of LH and FSH (Weber et al., 1982; Chapter 5), 
we also measured the levels of LRH and dopamine in 
hypophysial stalk plasma of tumor-bearing rats which 
were adrenalectomized at the time of tumor inocula-
tion. 
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2. Materials and methods 
2.1. Animals 
Adult male rats of the Buffalo strain were used. 
They were kept under 
rature (20-22°C) and 
controlled conditions of tempe-
light (14 h light, 10 h dark 
schedule), and they had free access to pelleted food 
and tap water. 
2.2. Experimental procedures 
Hyperprolactinemia was induced by injecting the 
animals subcutaneously with 0.2 rnl of a suspension of 
7315a tumor tissue as reported before (Weber et al.; 
Chapter 5). Hypophysial stalk blood was collected 
4-5 weeks after tumor inoculation. The animals were 
anesthetized with urethane (ethylcarbarnate, Brocades 
ACF, Maarssen, The Netherlands; l.l- l.2t'g/kg body 
weight, administered intraperitoneally as a 20% (w/v) 
solution in 0.9% NaCl and hypophysial stalk blood was 
collected at a rate of 6-10 1/min for l h as des-
cribed by Porter & Smith (1967) with some modifica-
tions (Gibbs & NeilL 1978; de Greef & Neill, 1979; 
Neill et al., 1979). Before the hypophysial stalk 
was cut, 500 IU heparin (Thromboliquine, Organon, 
Oss, The Netherlands) was injected into a polyethy-
lene cannula (0.58 mm internal diameter and 0.96 mm 
outside diameter) placed in the femoral artery and 
then a peripheral blood sample of about 1.5 ml was 
withdrawn from this arterial cannula for measurement 
of PRL, LH and FSH. In hypophysial stalk plasma do-
parnine and LRH were determined. Furthermore, the vo-
lume of hypophysial stalk plasma collected was meas-
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ured allowing calculation of the secretion rates for 
dopamine and LRH per hour. 
Two experiments were performed which were identi-
cal to those of the previous study (Chapter 5) so 
that direct comparisons between data from conscious 
(Chapter 5) and urethane-anesthetized (present study) 
rats could be made. In the first experiment, intact 
rats were inoculated with the tumor, while untreated 
intact rats served as controls. Each group contained 
8 animals. In the second experiment, 20 rats were 
castrated and received a 0.5 ern long capsule of poly-
dirnethylsiloxane (Talas, 
outside diameter 2.1 rom, 
with testosterone 
Zwolle, The Netherlands: 
inside diameter 1.5 rnrn) 
(Steraloids Inc., Wilton filled 
N.H.), inducing plasma testosterone concentrations of 
about l ng/ml. 13 of these 20 animals were adrena-
lectomized, and tumor inoculation was carried out di-
rectly after the operation. Castration and adrena-
lectomy were performed while the rats were under 
ether anesthesia. Adrenalectomized rats received 
0.9% NaCl solution (w/v) for drinking. 
2.3. Hormone determinations 
Concentrations of PRL, LH and FSH were measured by 
double-antibody radioimmunoassays in at least two di-
lutions of plasma as described earlier [PRL (de 
Greef & Zeilmaker, 1978); LH and FSH (Welschen et 
al., 1975)] using NIAMDD RP-l as standards. Plasma 
levels of testosterone were estimated by radioimmuno-
assay (Verjans et al., 1973). Levels of dopamine 
were determined by a high-pressure liquid chromato-
graphic-electrochemical method as described previous-
ly (Plotsky et al., 1978; de Greef et al., 1981). 
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Levels of LRH were measured by a double-antibody 
solid phase radioimmunoassay using an antiserum pur-
chased from Miles-Yeda (Israel), produced and charac-
terized according to 
tivity of this assay 
Koch et al. (1973). The sensi-
is 3-5 pg and up to 200 microl 
of plasma were assayed for LRH. This assay did not 
detect immunoreactive LRH in peripheral plasma of 
male rats. 
2.4. Statistical procedures 
Results are presented as means~ S.E.M .. A nonpa-
rametric test (Mann-Whitney U test) was used to es-
tablish significant differences between the groups of 
animals. Differences were considered to be signifi-
cant if p<O. 05. 
3. Results 
3.1. Effect of7315a tumor on levels of LRH and dopamine in 
hypophysial stalk plasma and on levels of LH, FSH and P RL in 
peripheral plasma in male rats 
The results of this experiment are presented in 
Table 6.1 .. In the tumor-bearing rats plasma levels 
of PRL increased 17-fold whereas the levels of LH and 
FSH in peripheral plasma were reduced by 45 and 70% 
respectively when compared to the controls. In the 
tumor-bearing animals the mean level of dopamine in-
creased from 6 to 13 ng/ml, whereas the mean level of 
LRH decreased from 520 to 201 pg/ml in hypophysial 
stalk plasma. 
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3.2. Effect of 7315a tumor on levels of LRH and dopamine in hypophysial 
stalk plasma and on levels of LH, FSH and P RL in peripheral plasma 
in adrenalectomized male rats 
The results of this experiment are given in Table 
6.2 .. Levels of PRL in peripheral plasma were incre-
ased more than 20-fold in animals bearing the 7315a 
tumor. As in the first experiment, plasma levels of 
LH and FSH were suppressed in tumor-bearing rats 
which were not adrenalectomized. However, when the 
adrenal glands were removed before tumor inoculation, 
plasma levels of LH and FSH were not significantly 
different from those measured in adrenalectomized 
control animals. Levels of LRH in hypophysial stalk 
plasma did not differ significantly in adrenalectom-
ized animals with or without the 7315a tumor, but 
were suppressed in tumor-bearing rats which were not 
adrenalectomized. Levels of dopamine in hypophysial 
stalk plasma increased in tumor-bearing animals with 
or without the adrenal glands when compared to ani-
mals without the tumor. 
4. Discussion 
Inoculation with the PRL- and ACTH-secreting 7315a 
tumor causes a suppression of peripheral levels of 
gonadotropins in both intact and castrated adult male 
rats. HOwever, the tumor does not inhibit gonadotro-
pin levels if adrenalectomy was carried out before 
tumor inoculation. Although in the present study the 
rats were anesthetized with urethane and underwent 
surgery in order to collect hypophysial stalk blood 
before a peripheral blood sample was taken, similar 
results as with conscious animals (Chapter 5) were 
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obtained. This finding that the anesthesia and surg-
ical procedure did not interfere with the effect of 
the tumor on the gonadotropin levels allowed the stu-
dy of the relationship between LRH and gonadotropins. 
In this study the levels of LRH measured in hypo-
physial stalk plasma of urethane anesthetized male 
rats are about 5-10 times those reported previously 
by Fink & Jamieson (1967). The differences in secre-
tion rates found in the two studies, however, are 
much lower (about 2-fold). The latter discrepancy 
might be due to the use of different antisera for 
measurement of LRH. 
In the present study it was shown that suppression 
of gonadotropins in male rats by the 7315a tumor is 
probably caused by decreased levels of LRH in hypo-
physial stalk plasma, suggesting a suppressed release 
of LRH from the hypothalamus. Other authors have 
also suggested, on the basis of indirect evidence, 
that the release of LRH is decreased in hyperprolac-
tinemic rats (Grandison et al., 1977; Gil-Ad et al., 
1978; Hodson et al., 1980; Hodson et al., 1981). 
The conclusion that the decreased peripheral levels 
of LH and FSH are caused by a decreased release of 
LRH into the pituitary portal blood of the 
tumor-bearing animals is supported by the finding 
that a cause-and-effect relationship exists between 
hypothalamic LRH secretion and serum gonadotropin 
levels (Eskay et al., 1977). However, a decreased 
sensitivity of the pituitary gland to LRH cannot be 
ruled out as additional factor. The latter presump-
tion is supported by the finding that stimulation of 
the release of LH and FSH during exogenous adminis-
tration of LRH is blunted in hyperprolactinemic rats 
(Winter & Loriaux, 1978; Vasquez et al., 1980). It 
is possible that this decreased responsiveness of the 
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pituitary gland to LRH is caused by the long-term ex-
posure to low levels of LRH. This might lead to a 
decreased content of LH and FSH in the pituitary 
gland or to a decreased number of pituitary LRH re-
ceptors. The first possibility does not seem likely 
since the levels of LH and FSH are increased in the 
pituitary glands of female rats bearing the same 
7315a tumor (Lamberts et al., 1981). 
sibility seems more likely since 
The second pes-
Clayton et al. 
(1982) reported that in orchidectomized rats the num-
ber of pituitary LRH receptors are regulated in a po-
sitive manner by hypothalamic LRH. However, it is 
still controversial whether a decreased number of pi-
tuitary LRH receptors is of consequence for the res-
ponsiveness of the pituitary gland to LRH (Wagner et 
al., 1979; Ferland et al., 1981; Frager et al., 
1981). 
As in the previous study (Chapter 5) it was found 
that the effects of the tumor on the levels of LH and 
FSH were only present in animals with adrenal glands. 
Furthermore, the present study reveals that the pres-
ence of the adrenal glands is also necessary for the 
effect that the tumor exerts on the release of LRH. 
The mechanisms by which the adrenal gland affects the 
levels of LRH in hypophysial portal blood and the 
levels of LH and FSH in peripheral plasma have not 
yet been elucidated. Adrenal weights and the levels 
of progesterone and corticosterone in peripheral 
plasma are increased after tumor inoculation (unpub-
lished results). It has been suggested that decre-
ased sensitivity of the pituitary gland to LRH in hy-
perprolactinemic female rats might be a consequence 
of increased progesterone secretion in these animals 
(Vasquez et al., 1980). It is also possible that 
adrenal steroids other than progesterone are respon-
133 
sible for the decreased release of LRH into the pitu-
itary portal blood. This, however, requires further 
investigation. 
Since the tumor 7315a secretes both PRL and ACTH, 
the suppression of LH and FSH might be due to PRL, 
ACTH or PRL plus ACTH. The observations that hyper-
prolactinemia induced by pituitary grafts has only a 
minor effect on pituitary-testicular function (Bartke 
et al., 1977; McNeilly et al., 1978) and that ad-
ministration of ACTH to intact male rats causes a 
marked reduction in the weights of the testes and ac-
cessory sex organs (Asling et al., 1951) suggest that 
the effects of tumor 7315a are mainly due to ACTH. 
It was observed in the present study that higher 
levels of dopamine in hypophysial stalk plasma were 
present in tumor-bearing animals than in control ani-
mals. Similar findings have been reported previously 
(Cramer et al., 1979; Gudelsky & Porter, 1980). In 
contrast to its effects on LRH levels in hypophysial 
portal blood, the tumor was also effective in alter-
ing dopamine levels in hypophysial stalk blood when 
the animals were adrenalectomized. It has been re-
ported that PRL administration to ovariectomized rats 
leads to an increased dopamine turnover in the median 
eminence and anterior hypothalamus, suggesting that 
the activity of dopaminergic neurons is enhanced (Gu-
delsky et al., 1976), leading to elevated levels of 
dopamine in hypophysial stalk blood (Cramer et al., 
1979; Gudelsky & Porter, 1980; present study). 
Hypothalamic dopamine has been suggested to be in-
volved in the regulation of LRH secretion (Gudelsky 
et al., 1976; Hokfelt & Fuxe, 1972). Although mor-
phological evidence is available that dopamine fibers 
might directly interact with LRH terminals 
(McNeill & Sladek, 1978), there is no substantial ev-
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idence that changes in hypothalamic dopamine are im-
portant for altered secretion of gonadotropins. Also 
clinical studies are not conclusive in this respect. 
Judd et al. (1978) observed a reduction of plasma 
concentrations of LH in women receiving an infusion 
with dopamine. In contrast, treatment of hyperpro-
lactinemic women with bromocriptine, a dopamine agon-
ist, resulted in an increase of gonadotropins (Porter 
et al., 1981). The present data of adrenalectomized 
tumor-bearing animals are also not supportive for the 
view that the increased secretion of dopamine by do-
pamine neurons is an important factor for reduction 
in plasma levels of LH and FSH. 
In conclusion, the present data clearly demon-
strate that the suppression of peripheral gonadotro-
pin levels in intact and castrated male rats bearing 
a PRL- and ACTH-secreting tumor can be explained by a 
decrease of LRH levels in hypophysial portal blood. 
However, the presence of the adrenal glands seems to 
be pivotal. Measurements of dopamine concentrations 
in hypophysial portal blood revealed an increase in 
tumor-bearing rats independent of the presence of the 
adrenal gland. It seems likely that the increased 
release of dopamine is caused by the high levels of 
PRL since PRL can affect its own secretion (see 11 In-
troduction ••) and long-term treatment of adrenalectom-
ized rats with ACTH does not decrease the release of 
PRL (unpublished findings). Thus, PRL can influence 
the hypothalamic release of dopamine, an established 
PRL release-inhibiting factor (MacLeod, 1976; Gibbs 
& Neill, 1978; Gibbs et al., 1979; de Greef 
& Neill, 1979; Neill et al., 1979). It is further-
more suggested that the changes in dopamine cannot 
account for the inhibitory effect on the secretion of 
LH and FSH in hyperprolactinemic tumor-bearing rats. 
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5. Summary 
The present study was concerned with the effects 
of a transplantable pituitary tumor secreting PRL and 
ACTH on the levels of LH and FSH in peripheral plasma 
and on the hypothalamic release of LRH and dopamine 
in the male rat. Male rats of the same age not ino-
culated with the tumor served as controls. 
Hypophysial stalk blood was collected from urethane-
anesthetized rats 4-5 weeks after tumor inoculation 
to measure their LRH and dopamine content. A peri-
pheral blood sample was withdrawn from the animals 
just before sectioning the hypophysial stalk to me as-
ure their content of LH, FSH and PRL. It was found 
that in the tumor- bearing rats the levels of PRL in-
creased 17-fold, whereas plasma levels of LH and FSH 
decreased by 45 and 70% respectively, when compared 
with the control rats. In the tumor-bearing rats, 
the secretion rate of dopamine in hypophysial stalk 
plasma increased from 1.4 to 4.1 ng/h, whereas the 
secretion rate of LRH decreased from 122 to 61 pg/h. 
However, when at the time of tumor inoculation adre-
nalectomy was performed, the tumor did not decrease 
plasma levels of LH and FSH and the secretion of LRH 
into hypophysial stalk blood any longer. The effect 
of the tumor on hypothalamic dopamine secretion was, 
however, still present in the adrenalectomized rats. 
It is concluded that the effect of the PRL- and 
ACTH-secreting pituitary tumor on plasma levels of LH 
and FSH requires the presence of the adrenal gland 
and that this effect is mediated through an inhibi-
tion of the hypothalamic release of LRH. Further-
more, this tumor increases the hypothalamic relese of 
dopamine independent of the presence of the adrenal 
gland. 
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CHAPTER 7 
APPENDIX TO CHAPTER 5 AND 6 
EFFECTS OF ACTH ON SERUM GONADOTROPINS AND 
WEIGHTS OF TESTES AND ACCESSORY SEX ORGANS 
1. Introduction 
The experiments described in Chapters 5-6 have 
supplied evidence that the presence of the adrenals 
is obligatory for the 7315a tumor to exert its inhi-
bitory action on gonadotropin secretion and on the 
weights of testes and accessory sex organs in male 
rats. This tumor secretes PRL, ACTH,p-endorphin and 
possibly other as yet unidentified products. It is 
difficult to assess from the previous work which of 
these hormones contributes to the stimulation of the 
adrenals in tumor-bearing animals. 
In an attempt to differentiate between effects of 
PRL and ACTH, the effects of high doses of ACTH on 
serum gonadotropins and weights of testes and acces-
sory sex organs of normal (non tumor-bearing) adult 
rats were studied. 
2. Materials and methods 
Adult male RxU rats were used, bred in our labora-
tory. Food, water and (after adrenalectomy) NaCl 
0.9% (w/v) were available ad libitum. ACTH (Synac-
then Depot) was given subcutaneously (10 U/day) dur-
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ing 10 days to intact rats (Exp. 1), to gonadectom-
ized rats with a subcutaneous implant of a l em long 
testosterone-filled silastic capsule (Exp. 2), and to 
adrenalectomized animals (Exp. 3). Animals treated 
similarly but without ACTH served as controls. On 
the eleventh day, 18 hours after the last ACTH injec-
tion, the animals were sacrificed by decapitation. 
Trunk blood was collected and assayed for LH, FSH, 
and testosterone as described in Chapter 4 and for 
corticosterone by protein binding. The weights of 
testes, prostates, seminal vesicles and adrenals were 
noted. 
Statistical analysis was by Student's t-test. 
P<0.05 was adopted to be significant. 
3. Results 
The results of the hormone determinations and 
organ weights are given in Table 7.1 and Table 7.2. 
In intact animals treated with ACTH (Exp. 1) a signi-
ficant suppression of LH, FSH and testosterone was 
observed, besides an increase of corticosterone lev-
els. The weights of testes and accessory sex organs 
were significantly reduced. There was a 6-fold in-
crease of adrenal weight. 
In gonadectomized animals with a small testosterone 
filled silastic capsule (Exp. 2), which has been 
shown not to affect serum LH and FSH (Chapter 5), ad-
ministration of ACTH resulted in a suppression of the 
post-castration rise of LH and FSH. 
Despite similar levels of testosterone in the 
ACTH-treated gonadectomized and the gonadectomized 
control group, there was a significant reduction of 
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the weights of prostates and seminal vesicles of the 
ACTH-treated group. 
Finally, no effects on FSH, testosterone and weights 
of testes and accessory sex organs were found in 
adrenalectomized animals treated with ACTH (Exp. 3). 
Although LH levels were significantly lower in the 
ACTH-treated than in the control group, this was not 
a consistent finding in repeated experiments: in a 
duplicate experiment the LH levels were 77.0 + 11.3 
and 34.5 + 1.6 ng/ml (n=4) in adrenalectomized rats 
with (20 U during 10 consecutive days) and without 
ACTH treatment, respectively. 
4. Discussion 
Although the present experiments have not yet been 
completed, it can be concluded from the data present-
ed that administration of high doses of ACTH to in-
tact adult male rats leads to hypogonadotropic hypo-
gonadism and decreased weights of testes and accesso-
ry sex organs. Furthermore, treatment with ACTH can 
suppress the post-castration rise of serum gonadotro-
pins. The reduction of the weights of accessory sex 
organs in the presence of constant testosterone lev-
els suggests a peripheral effect of products from the 
ACTH-stimulated adrenals on the handling of testos-
terone. 
If adrenalectomy was carried out before the adminis-
tration of ACTH, the suppressive effects on serum go-
nadotropin levels were no longer obtained. The 
weights of testes and accessory sex organs did not 
alter during treament with ACTH- From these observa-
tions it does not seem likely that ACTH has a direct 
effect on testes and accessory sex glands. 
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The present observations show that the presence of 
the adrenals is necessary for ACTH to cause a sup-
pression of LH, FSH, testosterone and weights of 
testes and accessory sex organs. The similarity 
between these experiments and those with rats bearing 
the PRL- and ACTH-secreting tumor 7315a indicate that 
in tumor-bearing animals most of the effects may be 
due to ACTH. 
It remains very tempting to examine which products 
from the tumor-stimulated or ACTH-stimulated adrenals 
are able, either alone or synergistically with pitui-
tary hormones, to exert their suppressive action on 
gonadotropins, testes and accessory sex organs. 
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CHAPTER 8 
EFFECTS OF PRL ON TESTICULAR FUNCTIONS USING AN 
INTRA TESTICULAR PITUITARY GRAFT 
R.F.A. Weber, M.P. Ooms and J.T.M Vreeburg 
1. Introduction 
In male rats hyperprolactinemia induced by pitui-
tary grafts results in suppression of gonadotropin 
secretion (Bartke et al., 1977; McNeilly et al. , 
1978) . Despite these reduced plasma levels of LH, 
the plasma levels of testosterone have been found to 
be normal (Bartke et al., 1977, McNeilly et al., 
1978). These data are in agreement with the observa-
tion that PRL enhances the sensitivity of the testis 
for LH (Bartke & Dalterio, 1976). Indeed, in hypo-
physectomized rats PRL maintains the capacity of the 
testis to bind LH (McNeilly et al., 1979; van Stra-
alen & Zeilmaker, 1982) and potentiates the effect of 
LH on testicular testosterone secretion (Purvis et 
al., 1979). In contrast other investigators have 
found that Leydig cells from intact rats bearing pi-
tuitary transplants under their kidney capsules have 
an impaired capacity to secrete testosterone 
(Sharpe & McNeilly, 1979). This reduced steroidogen-
ic capacity might be due to chronically suppressed 
serum gonadotropin levels as well as to a direct ef-
fect of PRL on Leydig cells (Sharpe & McNeilly, 
1979) . 
In order to assess direct effects of PRL on the 
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testes, pituitaries were implanted in the left 
testes, and the secretion of testosterone and the 
content of testosterone and DHT of these pituitary 
grafted testes were compared with those in the right 
testes. In addition, tubuli seminiferi in the neigh-
bourhood of the pituitary implant were inspected for 
histological changes. 
2. Materials and methods 
Adult male rats of the RxU strain, bred in our la-
boratory were caged under reversed lighting condi-
tions (dark phase between 9.00 and 19.00 h) and in 
constant temperature (20-22°C). Pelleted food (Hope 
Farms Standard Laboratory Diet) and tap water were 
always available. A pituitary from a female RxU rat 
was grafted under the tunica albuginea of the left 
testis, adjacent 
testis as indicated 
to the artery in the middle of the 
in Figure 8.1. In the right 
testis, a piece of cerebral cortex tissue was im-
planted. After 100 days 8 of these rats were sacri-
ficed by decapitation Their testes were frozen and 
stored in liquid nitrogen. Further work-up of the 
testes consisted of slicing the frozen testes into 7 
parts as shown in Figure 8.1. Directly after thawing 
the slices were homogenized in 0.9% NaCl (w/v) and 
stored at -20°C for androgen determination. In the 
testes of 4 rats in addition to testosterone also 
PRL, LH and FSH were determined. 
Another 5 rats were anesthetized with tribromoethanol 
(1.5 ml/100 gr BW 1:50 solution of tribromoethanol in 
saline, Avertine, Winthrop, i p.) 100 days after im-
plantation of a pituitary in the left testis. From 
!50 
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*** 
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0 
* • 2 
• E 
• 0 150 r-
1 00 
0 
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cranial 
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caudal 
Fig. 8.1 Testosterone levels (ng/g. mean± SEM) in 7 parts of the left 
(o--o) and right (e--.) testes 100 days after implantation of a pituitary 
in the left testes. The testes were divided as indicated. 
* P<O. 05 and *** P<O. 001 compared with corresponding parts of the 
right testes. 
these animals testicular venous blood was collected 
as described previously (de Jong et al., 1973). 
Directly after sampling testicular venous blood, the 
animals were killed by decapitation and trunk blood 
was collected The plasma samples were stored at -20°C 
for testosterone and PRL determinations. Subse-
quently the testes were removed and fixed in Bouin•s 
fluid for histological examination. 
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2.1. Hormone assays 
Serum levels of LH and FSH were determined using 
the antisera and procedures developed in our labora-
tory (Welschen et al., 1975). Serum levels of PRL 
were measured using materials and protocols supplied 
by the NIAMDD Rat Pituitary Hormone Distribution Pro-
gram. Concentrations of PRL, LH, and FSH are ex-
pressed in terms of the standard NIAMDD reference 
preparations (NIAMDD-LH RP-1, NIAMDD-FSH RP-1, and 
NIAMDD-PRL RP-1). The interassay coefficients of 
varation were 9% for FSH, 11% for LH, and 15% for 
PRL. The amounts of hormone that reduced binding of 
labeled hormone to 90% of that occurring in the ab-
sence of unlabeled hormone were 6 ng FSH, 2 ng LH, 
and 0.4 ng PRL. 
Testosterone concentrations in plasma and testicu-
lar tissue were determined by RIA (Verjans et al., 
1973). The inter-assay and intra-assay coefficients 
of variation were 15% and 7% respectively. In part 4 
testosterone and DHT were measured after thin-layer 
chromatography. Separation of testosterone from DHT 
and from 5a-androstane-3a:, 17/)-diol was performed on 
aluminium oxide pre-coated thin layer plates in the 
system toluene-acetone 85:15. Concentrations of tes-
tosterone and DHT were determined by radioimmunoassay 
using methods as described above. 
2.2. Statistical procedures 
All data are given as mean+ s.E.M. Statistical ana-
lysis was done by Student's t-test or analysis of 
variance (two factorial, i.e. parts of testes and 
left or right testis, block design). Significant in-
!52 
teractions were tested with simple main effect. With 
significant F ratios, the differences between the 
means were tested with LSD (Kirk, 1968). Differences 
were accepted to be significant when P<0.05. 
TABLE 8. 1 PRL levels (ng/g) in parts of testicular tissue 
of left and right testes after implantation of 1 
pituitary in the left testis (part D) • 
parts left 
3 290 ± 1 0 1 
2 188 ± 64 
593 ± 212 
*** 0 22798 ± 18967 
4 540 ± 208 
5 158 ± 71 
6 230 ± 93 
*** P<0.001 
0 
parts as indicated in Figure 8.1 
Values shown are means ± S.E.M. 
3. Results 
The PRL concentration in 
right 
60 ± 39 
85 ± 38 
48 ± 23 
318 ± 1 7 2 
80 ± 32 
90 ± 25 
90 ± 1 6 
the left testes 
(321 ~ 107 ng/g) without parts 0 was significantly 
(P<O.OS; Student's t-test) higher than in the right 
testes (72 ~ 25 ng/g). However, when corresponding 
parts of left and right testes were compared, it ap-
peared that only the PRL levels in parts 0 were sig-
nificantly different (Table 8.1). 
Only in parts 0 the LH and FSH concentrations 
could be detected (9. 4 + 2. 7 l'g/g and 18.3 + 7. 4 ,ug/g 
respectively) . 
The testosterone levels measured in testicular 
tissue are shown in Figure 8.1. Comparison between 
corresponding parts of left and right testes showed 
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that testosterone levels were significantly higher in 
5 of 7 parts of the left testes. In pieces of tes-
ticular tissue adjacent to the grafts (parts 4) tes-
tosterone and DHT were measured. It appeared that 
the mean levels of testosterone (119 + 14 ng/g) and 
DHT (25 + 6 ng/g) in parts 4 from the pituitary 
grafted testes were not significantly different from 
those (103 ~ 14 ng testosterone/g; 17 + 6 ng DHT/g) 
measured in the right testes. 
TABLE 8.2 Levels of PRL (ng/ml) and testosterone (ng/ml) in 
testicular and peripheral venous plasma in rats, 
100 days after implantation of a pituitary in the 
left testis. 
testicular venous plasma 
left right 
0* 
PRL 416 ± 118 
testosterone 84 ± 8.4 
* 
P<O.QS vs right 
P<O.OS vs peripheral 
59± 4.7 
49 ± 1 .5 
Values shown are means ± S.E.M. 
* 
peripheral no. of 
plasma rats 
41 ± 2.9 
1.04 ± 0.11 
5 
5 
PRL and testosterone levels in peripheral and tes-
ticular venous plasma are given in Table 8.2. PRL 
levels in testicular venous plasma from the left 
testes were significantly higher than from the right 
testes (P<0.05) and from levels in peripheral venous 
plasma (P<0.05). Moreover PRL levels in testicular 
venous plasma from the right testes were significant-
ly (P<0.05) higher than the levels in peripheral ven-
ous plasma. In contrast to the testicular testoster-
one concentrations no significant differences between 
the testosterone levels from the venous blood of left 
and right testes were found. As can be seen in Fig-
ure 8.2 the spermatogenesis in tubuli adjacent to the 
implanted pituitary did not show any alterations. 
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Fig. 8.2a Testicular tissue adjacent to pituitary tissue (PIT), 100 days 
after implantation of the pituitary into the testis ( xSO). 
Fig. 8.2b Higher magnification (x320) of Fig. 8.2a, showing pituitary 
tissue (PIT), interstitia! tissue (IS) and seminiferous tubuli (ST). 
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4. Discussion 
our data demonstrate that a pituitary implanted in 
the testis secretes appreciable amounts of PRL for a 
long period of time: 100 days after implantation of 
the pituitary into the testis, more than 400 ng 
PRL/ml was estimated in its venous plasma. The PRL 
levels in peripheral plasma, however, are not higher 
than those found normally in this strain of rats. 
This observation is in accordance with the finding 
that in the presence of only one pituitary under the 
kidney capsule, peripheral plasma levels of PRL are 
not significantly elevated (McNeilly et al., 1978). 
As could be expected, the wedge of testicular tissue 
which contained the pituitary graft, had a very high 
concentration of PRL and caused an increase in PRL in 
the left testis. 
In addition to the rise in the testicular concen-
tration of PRL, als testosterone increased. Since 
the rise in the tissue testosterone concentration was 
not accompanied by a rise in testosterone secretion, 
an increase in the binding capacity for testosterone 
might have occurred. The increase in testicular tes-
tosterone concentration might have been due to PRL 
although LH secretion by the pituitary graft cannot 
be ruled out completely, since the pituitary grafted 
part of the testis contained appreciable amounts of 
LH. In the other parts of the left testis, the LH 
concentrations were below the limit of detection. 
This observation and the fact that testosterone in 
concentrations much lower than present in the testis 
are capable to inhibit the hypophysial LH secretion 
(Drouin & Labrie, 1976) makes it probable that the LH 
secretion by the pituitary grafts have been negligi-
ble. 
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In a variety of studies, PRL has been shown to in-
hibit the Sa-reductase activity in the adrenal (Wi-
torsch & Kitay, 1972), but the effects of PRL on 
Sa-reductase activity in accessory sex glands are in-
conclusive (Yamanaka et al., 1975; Manandhar & Tho-
mas, 1976; Prins & Lee, 1982). The present study 
demontrates clearly that in testicular tissue adja-
cent to the pituitary graft the ratio between testos-
terone and DHT is not changed, suggesting a normal 
Sa-steroid reductase activity despite elevated PRL 
levels. 
The observations that spermatogenesis in tubuli 
adjacent to the implanted pituitary seemed to be nor-
mal, and that the steroidogenic capacity of the 
testis was not inhibited, are in accordance with our 
previous study (Chapter 5) in which was reported that 
extremely high PRL levels due to a PRL- and ACTH-se-
creting tumour do not affect testicular weight or 
serum testosterone in adrenalectomized rats. 
5. Summary 
Pituitary glands were grafted under the capsule of 
the left testis to induce high levels of PRL in this 
organ- 100 Days after implantation, significantly 
increased levels of PRL were found in the tissue and 
the venous plasma of the left testis. Although the 
levels of testosterone in testicular venous plasma 
were not elevated, the testicular content of testos-
terone was increased when compared to the right 
testis. 
The ratio of testosterone and DHT was not affected in 
the pituitary grafted testis. 
Since the tubuli seminiferi adjacent to the pitui-
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tary graft appeared to be completely normal, it is 
concluded that in the rat high levels of PRL have no 
direct inhibitory effect on testicular functions. 
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SUMMARY 
In this thesis some effects of PRL on reproductive 
functions have been investigated 
PRL-secreti~g pituitary adenoma. 
animal model has been used: 
For 
in men with a 
comparison an 
In. rats hyperprolactinemia has been i:r~duced by sub--
cutaneous inoculation of a PRL- and ACTH-secreting 
transplantable pituitary t~~or. 
lbe local effects of PRL on ·t-esticular functions 
have been studied by implantation of a pituitary 
in a testis. 
Hyperprolactinemia in man 
Tl-,_e sy:nptoms c:!: 11yperprolact.i:nemia in me=: -,vit::. o. 
~ituitary ~denoma are; as ~ndicated ln ~any reccrts 
~ Cl1.apter l) f nostly 3x:.e ·t..·::J lccal effects o£ "":.:"le ·t'.lmcr 
on para- and suprasellar tlssues. Patients may pre-
sent "~Nith l1.eadachet impair·ed vision, visual field de-
fects, paresls of the eyem'J.scles and hypopituitarism. 
Loss c£ libido and potencyr which sympt.oms may -r:e-
t::.r0spectivel.y be present for a long period, ar,e co:r-
sidereC by sany authors to be ·typical feat0..2res for 
:::'.ale hyperprolactinemia. Gynecomastia and 9alactor-
rhea are uncormnon findings, 
respect to function of 
triuch o£ the research 
the hypothalamic-pitui-
tary-testicular axis in hyperprolactinemic uen re-
ported over ·the past few years is still controver-
sial. The basal serum levels of LE and FSH may be 
normal or decreased and their response to LRH may be 
normal or blunted. Serum testosteron levels have 
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been found subnormal, even in the presence of normal 
basal and LRH-stimulated LH and FSH levels. 
Furthermore serum testosterone levels may show a nor-
mal response to the administration of hCG. It is 
difficult to draw conclusions from the data present.ed 
in the various papers since most of the reported ser-
ies comprised men with macroadenomas or men who had 
been treated before the time of presentation. 
In Chapter 3 the findings of 32 men with a 
PRL-secreting pituitary adenoma have been discussed. 
A macroadenoma was present in 19 patients, who pre-
sented with headache~ visual field defects and/or im-
paired vision and hypopituitarism. The majority of 
these 19 men had loss of libido or impotence. 
Gynecomastia and galactorrhea were present in three 
of them. In the presence of high serum PRL levels 1 
the basal levels of LH and FSH were normal but their 
response to LRH was blunted. Furthermore low serum 
testosterone levels were found in most of the pati-
ents. It was not possible to show whether the sup-
pression of the pituitary-gonadal axis in these 19 
patients with a macroadenoma was due to the hyperpro-
lactinernia or to the loss of function of the gonado-
tropic cells by compression and/or destruction caused 
by the tumor itself. In support of this last pre-
sumption is the loss of other anterior pituitary 
functions in these 19 men harboring a macroadenorna. 
Loss of pituitary-thyroidal function 8 measured by 
basal and TRH-stimulated TSH levels, subnormal levels 
of 11-deoxycortisone after the administration of me-
tyrapone representing an insufficient pituitary-
adrenal axis and panhypopituitarism have been ob-
served. The other 13 out of 32 hyperprolactinemic 
men had been selected from a group of 598 infertile 
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men with sperm abnormalities- The low incidence of 
hyperprolactinernia in our series of infertile men was 
a confirmation of the literature. Only 2 of these 13 
patients suffered from diminished libido. The others 
had no complaints of impotence or loss of libido. 
The 2 patients with diminished libido had a macroade-
noma, the others a microadenoma. PRL levels in this 
group of 13 patients were much lower compared to the 
first group of 19 men. Gynecomastia and galacthor-
rhea were present in 2 patients. In contrast to the 
findings in the first group, the anterior pituitary 
functions and especially the basal and LRH-stimulated 
LH and FSH levels were normal. Furthermore testes-
teron levels were normal in most of the patients. In 
this group of infertile patients with microadenomas, 
that probably cannot compress and/or destruct normal 
pituitary tissue, the only slightly increased PRL 
levels are not able to suppress the pituitary-gonadal 
axis- Nevertheless treatment with bromocriptine was 
given to study the effects of normalising PRL levels 
on fertility. Two patients fertilized before, 4 men 
during treatment. None of these 4 men showed im-
provement of their sperm qualities, while testoster-
one levels significantly increased as has been re-
ported in the literature. Another common finding was 
the restoration of libido in the 2 men with a macroa-
denoma in the group of infertile patients. 
We have suggested that according to our findings 
the suppression of the pituitary-gonadal axis in pa-
tients with a PRL-secreting macroadenoma is mainly 
due to local compression and/or destruction of normal 
pituitary tissue. Improvement of libido and incre-
ment of testosterone levels during PRL-reducing ther-
apy may indicate an effect of PRL. 
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Hyperprolactinemia in the rat 
Subsequent to possible effects of hyperprolacti-
nemia on libido in man, copulatory behavior has been 
studied in hyperprolactinemic male rats (Chapter 4). 
Hyperprolactinemia has been induced by the inocula-
tion of the PRL- and ACTH-secreting tumor 7315a sub-
cutaneously. Two Weeks after inoculation serum PRL 
levels begin to rise up to several micrograms per ml 
5 to 6 weeks after inocultion. 
The presence of the tumor caused hypogonadotropic 
hypogonadism in adult male rats (Chapter 5). The de-
creasing testosterone levels during growth of the 
tumor forced us to study copulatory behavior in cas-
trated animals with constant testosterone levels by 
placing subcutaneously a testosterone filled silastic 
tube. Increment of PRL concentrations induced a re-
markable change of copulatory behavior. The number 
of mounts increased very much and the time which 
elapsed between the first mount and ejaculation in-
creased. The number of intromissions before ejacula-
tion did not change. The increased number of mounts 
was probably due to a relative inability to intromit 
properly during hyperprolactinemia. 
Since the tumor secretes both PRL and ACTH, re-
sulting in large adrenals (Chapter 5) we have also 
studied copulatory behavior of adrenalectomized 
tumor-bearing animals. Copulatory behavior of adre-
nalectomized tumor-bearing animals, with very high 
serum PRL levels, and of adrenalectomized control an-
imals did not differ. 
From these observations can be concluded that even 
very high PRL levels have no effect on copulatory be-
havior of the adrenalectomized male rat. 
With respect to the effects of PRL on serum LH, 
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FSH and testosterone levels in the male rat two dif-
ferent observations have been described in the liter-
ature (Chapter 2). A moderate increase of serum PRL 
level, induced by ectopic pituitaries, causes sup-
pression of LH- and FSH-concentrations, while serum 
testosterone levels remain normal. Moreover, ectopic 
pituitaries are able to suppress the post-castration 
rise of LH and FSH. The inoculation of PRL-secreting 
tumors is accompanied with very high PRL levels, 
atrophy of the testes and accessory sex glands and 
suppression of LH, FSH and testosterone. 
In Chapter 5 levels of LH, FSH and testosterone 
and the weights of testes, accessory sex glands and 
adrenals in adult male rats with the PRL- and 
ACTH-secreting tumor 7315a are reported and have been 
discussed. 
Tumor-inoculation in intact animals resulted in a 
decrease of serum LH, FSH and testosterone levels and 
in a decrease of the weights of testes and accessory 
sex glands. The weights of the adrenals were very 
much increased. Furthermore mammary gland tissue was 
fully developed and contained a lot of milk. The 
tumor was also able to suppress the post-castration 
rise of LH and FSH. If adrenalectomy was carried out 
before tumorinoculation the rise of LH and FSH after 
castration was normal, while LH, 
levels did not change in 
tumor-bearing animals despite 
FSH and testosterone 
adrenalectomized 
very high serum PRL 
levels- The observations in castrated animals have 
been done in the presence of constant subnormal tes-
tosterone concentrations, caused by subcutaneously 
placed testosterone-filled silastic capsules. 
Although comparable testosterone levels were present 
in adrenalectomized and non-adrenalectomized tumor-
bearing rats, at autopsy the weights of accessory sex 
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glands were decreased in the latter group. 
The regulation of LH- and FSH-secretion in 
tumor-bearing animals have been further investigated 
(Chapter 6) by determinations of dopamine and LRH in 
hypophysial stalk blood. Numerous studies have shown 
that the secretion of hypothalamic dopamine, the most 
important "PRL-inhibiting factor", is regulated by 
PRL via a short-loop positive feed-back mechanism. 
Moreover, some authors state that dopamine is in-
volved in the secretion of LRH by the hypothalamus. 
Disturbances in the secretion of LH and FSH during 
hyperprolactinemia might be explained by a suppres-
sive action of dopamine The decrease of LH and FSH 
in intact rats bearing the 7315a tumor might be ex-
plained by a decrease of LRH in hypophysial stalk 
blood. Both the dopamine concentration and the se-
cretion rate of dopamine in hypophysial stalk blood 
were increased. Similar serum concentration of LH 
and FSH were found in tumor-bearing and non-tumor-
bearing rats if adrenalectomy was performed before 
tumor-inoculation. Also the LRH concentrations in 
hypophysial stalk blood were not different. Dopamine 
levels, however, were increased in hypophysial portal 
blood of tumor-bearing animals. 
The results of the experiments described in 
Chapter 5 and 6 indicate that hyperprolactinemia in 
adrenalectomized animals bearing the PRL- and ACTH-
secreting 7315a tumor is not accompanied by a sup-
pression of LH and FSH. In Chapter 7 is described 
the investigation as to which factor from the 7315a 
tumor, which secretes besides PRL and ACTH at least 
~-endorphin, is able to suppress the secretion of LH 
and FSH in the presence of the adrenals. The ad-
ministration of ACTH subcutaneously to intact adult 
male rats caused a suppression of serum LH, FSH and 
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testosterone and a decrease of the weights of testes 
and accessory sex glands. Moreover, the administra-
tion of ACTH was able to suppress the post-castration 
rise of LH and FSH. In castrated rats with compar-
able testosterone levels obtained by the previously 
mentioned testosterone implantation, the weights of 
accessory sex gland of the ACTH-treated animals were 
less than those of the non-treated rats. These find-
ings are similar to those in animals bearing the 
7315a tumor as described in Chapter 5 and 6. 
Although hyperprolactinemia in adrenalectomized 
animals with the 7315a tumor did not influence serum 
testosterone concentrations (Chapter 5), in the li-
terature (Chapter 2) stimulatory effects of PRL on 
gonadal function of the rat have also been described. 
In Chapter 8 gonadal functions have been further 
investigated. Implantation of a pituitary in l 
testis caused high PRL levels both in testicular tis-
sue and in testicular venous blood from the testis 
with the pituitary transplant. Hyperprolactinemia 
was not present in peripheral blood. 100 Days after 
implantation the testosterone levels in testicular 
tissue of the whole testis with the pituitary implant 
were higher than in the 
concentrations did not 
venous blood or in 
other testis. Testosteron 
change either in testicular 
peripheral venous blood. 
spermatogenesis even in tubuli adjacent to the pitui-
tary graft seemed to be completely normal. 
The experiments presented in this thesis in gener-
al do not support the accepted opinion that PRL it-
self either in man or in the male rat is able to dis-
turb reproduction. In the male rat bearing the PRL-
and ACTH-secreting tumor 7315a the presence of the 
adrenals is obligatory to suppress serum LH, FSH and 
testosterone concentrations. Furthermore, adrenals 
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stimulated with pharmacological doses of ACTH are 
also able to suppress LH, FSH and testosterone secre-
tion- Moreover, the stimulatory effects of testos-
terone on accessory sex glands are inhibited by a 
product from the adrenal cortex. 
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SAMENV ATTING 
In dit proefschrift wordt een paging ondernomen om 
enkele effecten, die PRL heeft op reproductieve func-
ties nader te bestuderen bij mannen met een PRL-pro-
ducerend hypofyseadenoom. 
Ter vergelijking wordt gebruik gernaakt van een 
proefdiermodel: 
- Bij de rat wordt hyperprolactinaemie geinduceerd 
door subcutane inoculatie van een PRL- en ACTH-
secernerende transplantabele hypofysetumor. 
- De locale effecten van PRL op testiculaire functies 
worden bestudeerd door implantatie van een hypofyse 
in een testikel 
Hyperprolactinaemie bij de man 
De verschijnselen bij de man met hyperprolactinae-
mie als gevolg van een hypofyseadenoom worden, zoals 
uit vele studies (Hoofdstuk 1) blijkt, veelal bepaald 
door de invloed die het adenoom heeft op de omlig-
gende structuren, gepaard gaande met hoofdpijnklach-
ten, visusdaling en/of gezichtsvelduitval, oogspier 
parese en hypopituitarisme. Libidoverlies en impo-
tentieklachten, welke retrospectief bij het merendeel 
van de mannen al geruime tijd aanwezig zijn, worden 
door vele auteurs als kenmerkend voor hyperprolacti-
naemie beschouwd. 
Gynaecomastie en galactorrhoe zijn weinig frequent 
voorkomende verschijnselen. 
OVer het functioneren van het hypothalamus-hypofyse-
gonadensysteem zijn de beschrijvingen nogal uiteen-
lopend. De basale waarden van LH en FSH kunnen nor-
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maal of verlaagd zijn en vertonen een normale of ver-
minderde response op toediening van het LRH. Het 
serum testosteron is vaak verlaagd, zelfs in de 
aanwezigheid van normale basale en met LRH gestimu-
leerde LH- en FSH-waarden. Bovendien kan het serum 
testosteron een volledig normale reactie vertonen na 
toediening van hCG. Een probleem bij het beoordelen 
van de vele onderzoekingen van hyperprolactinaemische 
mannen is, dat het merendeel van de mannen een macro-
adenoom heeft of dat er vaak al een behandeling is 
voorafgegaan aan het tijdstip van onderzoek. 
In Hoofdstuk 3 worden de bevindingen bij 32 mannen 
met een PRL-producerend hypofyseadenoom besproken. 
Bij 19 van hen was er sprake van een macroadenoom. 
Zij presenteerden zich met klachten over hoofdpijn, 
gezichtsvelduitval en/of visusvermindering en hypopi-
tuitarisme- Het merendeel van deze 19 patienten had 
daarnaast klachten over impotentie en libidoverlies. 
Bij lichamelijk onderzoek had 3 van de 19 mannen gy-
naecornastie en galactorrhoe. In deze groep van 19 
mannen werden hoge serum PRL waarden gemeten. De ba-
sale waarden van LH en FSH waren normaal of laag nor-
rnaal, doch de response op toediening van LRH was on-
voldoende. Bovendien werden bij de meeste patienten 
lage serum testosteronspiegels gemeten- Het was niet 
mogelijk om te onderscheiden of de gesupprimeerde hy-
pofyse-gonadenas bij de 19 patienten met een rnacroa-
denoom het gevolg was van de hoge serum PRL waarden, 
of dat de tumor zelf door compressie en/of destructie 
van het normale hypofyseweefsel aanleiding gaf tot 
functieverlies van de gonadotrope cellen. Deze 
laatste veronderstelling werd gesteund door het feit 
dat bij de 19 mannen met een macroadenoom oak andere 
hypofyse-VOOrkwabfuncties gestoord Waren. ZOWel uit-
val van de hypofyse-schildklieras, gemeten aan basale 
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en met TRH gestimuleerde TSH-concentraties, uitval 
van de hypofyse-bijnieras, gemeten aan 11-deoxycor-
tisol waarden na toediening van metyrapone, 
volledig panhypopituitarisme werden gezien. 
als een 
De overige 13 van de 32 hyperprolactinaemische 
mannen werden geselecteerd uit een groep van 598 man-
nen, die werden onderzocht wegens infertiliteit. 
Aangenornen werd dat de infertiliteit bij deze mannen 
berustte op de sperma afwijkingen. De lage inciden-
tie van hyperprolactinaernie bij infertiliteit, zeals 
in de literatuur beschreven, werd bevestigd. Bij 11 
van deze 13 patienten war en er geen klachten over i-
potentie of libidoverlies, bij 2 van hen was er 
~r~e van libidovermindering. De laatste 2 patien-
ten hadden een macroadenoom, de overigen hadden een 
microadenoom. Ten opzichte van de eerdergenoemde 
groep van 19 patienten waren de PRL-spiegels veel 
lager. Gynaecomastie en galactorrhoe werd bij 2 van 
de 13 patienten gezien. 
In tegenstelling tot in de eerste groep waren de 
hypofysevoorkwabsfuncties en met name de basale en 
gestimuleerde LH- en FSH-waarden normaal. Bovendien 
waren de testosteronconcentraties veelal normaal. In 
deze groep van infertiele mannen met een microade-
noom, waarbij locale compressie en/of destructie van 
het normale hypofyseweefsel waarschijnlijk niet voor-
komt, is het weliswaar slechts licht verhoogde serum 
PRL niet in staat de hypofyse-gonadenas te onder-
drukken. 
Nietternin werd een behandeling met bromocriptine 
ingesteld om de effecten van normalisering van PRL op 
de fertiliteit te bestuderen. Twee mannen fertili-
seerden neg voor de therapie, 4 mannen tijdens behan-
deling met bromocriptine. Bij deze 4 mannen was er 
geen verbetering van de spermakwaliteiten, wel zagen 
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wij een significante stijging van het serum testos-
teron, zoals ook in de literatuur beschreven wordt. 
Een andere in de literatuur veelvuldig vermelde be-
vinding was herstel van libido bij de 2 mannen met 
een macroadenoom in deze groep. 
Op grand van deze gegevens wordt gesuggereerd dat 
bij patienten met een PRL-producerend macroadenoom de 
suppressie van de hypofyse-gonadenas voornamelijk be-
paald wordt door locale compressie en/of destructie 
van het normale hypofyseweefsel. Verbetering van li-
bido en stijging van serum testosteronwaarden tijdens 
PRL verlagende therapie kunnen wijzen op een effect 
van PRL zelf. 
Hyperprolactinaemie bij de rat 
Naar aanleiding van mogelijke effecten van hyper-
prolactinaemie op de libido bij de man is het copula-
tiegedrag van de hyperprolactinaemische rat bestu-
deerd (Hoofdstuk 4). Hyperprolactinaemie werd gein-
duceerd door subcutane inoculatie met de PRL- en 
ACTH-secernerende tumor 7315a. Ongeveer 2 weken na 
inoculatie begon het serum PRL te stijgen om 5 tot 6 
weken na inoculatie een concentratie van enkele rni-
crogrammen per ml te bereiken. 
De aanwezigheid van de tumor leidde bij volwassen 
mannelijke ratten tot hypogonadotroop hypogonadisme 
(Hoofdstuk 5). Bet feit dat de testosteronspiegel 
tijdens het groeien van de tumor sterk daalde maakte 
het noodzakelijk om het copulatiegedrag te bestuderen 
bij gegonadectomeerde dieren met constante serum tes-
tosteronwaarde.n door rniddel van subcutane plaatsing 
van een met testosteron gevuld silastic buisje. 
TijQens het stijgen van de PRL concentratie werd een 
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opvallende verandering in het copulatiegedrag waarge-
nomen. Er was een sterke toename van het aantal be-
klimmingen en het duurde langer, gerekend vanaf de 
eerste beklimming, tot de ejaculatie. Ret aantal in-
tromissies voorafgaande aan ejaculatie veranderde 
niet. De toename van het aantal beklimmingen was mo-
gelijk het gevolg van een relatief onvermogen een 
goede intromissie te verkrijgen tijdens hyperprolac-
tinaemie. 
Aangezien de tumor zowel PRL als ACTH secerneert, 
hetgeen o.a. resulteert in een sterke vergroting van 
de bijnieren (Hoofdstuk 5) heben wij oak het copula-
tiegedrag van bijnierloze tumordragende dieren bestu-
deerd. Het copulatiegedrag van 
nierloze dieren (die zeer hoge 
tumordragende bij-
PRL-spiegels hadden) 
was identiek met dat van bijnierloze controledieren. 
Op grand van deze waarneming kan worden geconclu-
deerd dat zelfs sterk uitgesproken hyperprolactinae-
mie geen invloed heeft op het copulatiegedrag van de 
bijnierloze mannelijke rat. 
De in de literatuur vermelde resultaten van ex-
perimenten betreffende de invloed van PRL op LH, FSH 
en testosteron in het bloed bij de rat zijn nogal ui-
teenlopend (Hoofdstuk 2). Een matige PRL-verhoging, 
geinduceerd door ectopische hypofysen, gaat gepaard 
met een daling van de LH- en FSH-concentraties, 
terwijl het serum-testosteron normaal blijft. 
Ectopische hypofysen zijn tevens in staat om de 
stijging van serum LH en FSH, die optreedt na castra-
tie, te onderdrukken. De inoculatie van PRL-secerne-
rende tumoren bij de rat leidt tot sterk verhoogde 
PRL-spiegels, atrofie van testes en accessoire klie-
ren en een verlaging van LH, FSH en testosteron. 
In Hoofdstuk 5 worden de resultaten met betrekking 
tot LH, FSH, testosteron en gewichten van testes, ac-
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cessoire klieren en bijnieren besproken bij volwassen 
mannelijke ratten met de PRL- en ACTH-secernerende 
tumor 7315a. 
Tumorinoculatie bij intacte ratten leidde tot dal-
ing van LH, FSH en testosteron en tot een gewichts-
daling van testes en accessoire klieren, terwijl de 
bijnieren sterk in gewicht toenamen. Het mamrnaklier-
weefsel was toegenomen en bevatte veel melk. De 
tumor was tevens in staat om de post-castratiestij-
ging van LH en FSH te onderdrukken. Indien voor de 
tumorinoculatie adrenalectomie werd uitgevoerd vond 
er na castratie een normale stijging van het LH en 
FSH plaats, terwijl de LH- FSH- en testosteronspie-
gels bij uitsluitend geadrenalectorneerde tumordra-
gende ratten niet veranderden ondanks 
stijgende PRL-concentraties in het serum. 
de sterk 
De waar-
nemingen bij gecastreerde ratten werden gedaan in de 
aanwezigheid van een constante, doch lage serum tes-
tosteronspiegel, verkregen door subcutane irnplantatie 
van een met testosteron gevuld silastic buisje. Bij 
autopsie bleek dat, ondanks het feit dat de serum 
testosteronwaarden bij geadrenalectomeerde en niet 
geadrenalectomeerde ratten ongeveer even hoog waren, 
er een daling optrad van de gewichten van accessoire 
klieren in de laatstgenoemde groep. 
Vervolgens (Hoofdstuk 6) werd de regulatie van de 
LH- en FSH-secretie bij tumordragende dieren nader 
bestudeerd door bepaling van dopamine en LRH in hy-
pofysesteelbloed. De afgifte van dopamine, de belan-
grijkste "PRL-inhibiting factor", wordt zeals uit 
vele studies blijkt via een short-loop positief feed-
back-mechanisme gereguleerd door PRL. Tevens is do-
pamine volgens sommige auteurs betrokken bij de se-
cretie van LRH door de hypothalamus. Bij stoornissen 
in de secretie van LH en FSH tijdens hyperprolacti-
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naemie zou dopamine een remmende factor kunnen zijn. 
De daling van LH en FSH in het serum bij intacte rat-
ten na inoculatie van de 7315a tumor bleek verklaard 
te kunnen worden door een da- ling van LRH in het hy-
pofysesteelbloed. Tevens waren zowel de dopaminecon-
centratie in het hypofysesteelbloed als de dopami-
neafgifte aan het hypofysesteelbloed verhoogd. Na 
adrenalectomie en tumorinoculatie werden gelijke LH-
en FSH-concentraties gevonden in het serum van tumor-
en niet-tumordragende ratten. De LRH-spiegels in bet 
hypofysesteelbloed waren eveneens gelijk. 
Daarentegen waren de dopaminewaarden in bet hypofy-
sesteelbloed van tumordragende dieren verboogd. 
De resultaten van experimenten beschreven in 
Hoofdstuk 5 en 6 wijzen erop dat hyperprolactinaemie 
bij bijnierloze dieren met de PRL- en ACTH-secerne-
rende tumor 7315a niet leidt tot suppressie van serum 
LH en FSH. In Hoofdstuk 7 wordt beschreven, hoe is 
nagegaan welke factor uit de 7315a tumor, die naast 
PRL en ACTH tenminste ook nog ~-endorphine secer-
neert, in staat is om in de aanwezigheid van de 
bijnieren de secretie van LH en FSH te onderdrukken. 
Subcutane toediening van ACTH aan volwassen, intacte 
mannelijke ratten veroorzaakte een daling van LH, FSH 
en testosteron in het serum en een vermindering van 
de gewichten van testes en accessoire klieren. 
Verder was de toediening van ACTH aan ratten, die ge-
castreerd werden, in staat om de te verwachten stij-
ging van LH en FSH te onderdrukken. Bij gelijke tes-
tosteronwaarden, bij de gecastreerde ratten verkregen 
door de genoemde testosteron implantatie, waren de 
gewichten van de accessoire klieren van de met ACTH 
behandelde ratten ratten lager dan van die van de 
dieren, die geen ACTH kregen. Deze bevindingen zijn 
identiek met die bij dieren met de 7315a tumor zoals 
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beschreven in Hoofdstuk 5 en 6. 
Ofschoon de hyperprolactinaemie bij bijnierloze 
dieren met de 7315a tumor geen invloed bleek te heb-
ben op de testosteronconcentratie in het serum 
(Hoofdstuk 5) worden in de literatuur (Hoofdstuk 2) 
aan PRL oak stirnulerende effecten op de functie van 
de gonaden van de rat toegeschreven. 
In Hoofdstuk 8 wordt nader onderzoek van de gena-
dale functies beschreven. Door irnplantatie van een 
hypofyse in 1 testikel werden zowel locaal in het 
weefsel 
testikel 
als in het testiculaire veneuze bleed van de 
met een hypofyse transplantaat hoge 
PRL-waarden verkregen, terwijl in het perifere veneu-
ze bleed geen hyperprolactinaemie ontstond. 100 
Dagen na de implantatie was het testosterongehalte 
van de gehele testikel met de ectopische hypofyse 
hager dan van de andere testikel. Noch in het testi-
culaire veneuze bleed, noch in het perifere veneuze 
bloed werden veranderingen van de testosteronconcen-
traties gezien. Verder bleek de spermatogenese, 
zelfs in tubuli direct naast het hypofysetransplan-
taat gelegen, volledig ongestoord te zijn. 
De in dit proefschrift beschreven experimenteD 
geven geen steun aan de in de literatuur geldende op-
vatting dat PRL zelf bij de man en de mannelijke rat 
aanleiding geeft tot stoornissen in de voortplanting. 
In de mannelijke rat met de PRL- en ACTH-secernerende 
73l5a tumor is de aanwezigheid van de bijnier vereist 
voor de daling van LH, FSH en testosteron. 
De door farmacologische doses ACTH gestimuleerde 
bijnier blijkt in staat te zijn de LH-, FSH- en tes-
tosteronsecretie te onderdrukken. Ook de stimule-
rende werking van testosteron op accessoire klieren 
wordt geremd door een bijnierschorsproduct. 
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NAWOORD 
Het schrijven van een wetenschappelijk verslag is 
slechts de summiere weergave van een onderzoek waar-
aan de schrijver tegenwoordig vaak een bescheiden 
aandeel heeft geleverd. Velen ben ik dan ook dank 
verschuldigd bij het volbrengen van dit proefschrift. 
Mijn dank gaat in de eerste plaats uit naar de afde-
lingen Biochemie II (Hoofd, Prof. Dr. H.J. van der 
Molen), Fysiologie II (Hoofd, Prof. Dr. J.J. van der 
Werff ten Bosch) en Inwendige Geneeskunde III (Hoofd, 
Prof. Dr. J C. Birkenhager), die mij in staat hebben 
gesteld om in 1979 een aanvang te maken met het on-
derzoek, dat voor een groat deel plaats vond op de 
afdeling Fysiologie II. Met veel plezier denk ik 
terug aan de ongedwongen werksfeer op deze afdeling, 
waar Jan Vreeburg rnij zeer vele aspecten van het be-
drijven van wetenschap heeft bijgebracht en ik mag 
mij gelukkig prijzen dat de hechte samenwerking die 
hieruit ontstaan is de komende jaren voortgezet kan 
worden. Veel dank ben ik ook verschuldigd aan Steven 
Larnberts, die als mede-projectleider met enthousiasme 
en opbouwende kritiek mij heeft gestimuleerd de vele 
idee9n, die tijdens het onderzoek ontstonden, verder 
uit te werken. Niet weg te denken in dit samenwer-
kingsverband is Marja Ooms, die het merendeel van de 
laboratoriumbepalingen heeft gedaan en voortdurend 
bereid was en is om behulpzaam te zijn bij de vele 
praktische aspecten van experimenteel werk. Frank de 
Jong en Focko Rommerts maakten mij vertrouwd met de 
isolatie-technieken van Leydigcellen en de sampling 
van testiculair veneus bleed. De vaak heftige dis-
cussies met hen zijn onvergetelijk. De mogelijkheid 
om op 3 afdelingen werkzaam te zijn biedt uiteraard 
177 
de mogelijkheid met bet werk van velen in contact te 
komen. Hieruit voortvloeiend was de samenwerking met 
Wim de Greef, die door sampling van hypofysesteel-
bloed en de serumbepaling van dopamine een belang-
rijke bijdrage heeft geleverd aan dit proefschrift. 
Serum-LRH in hypofysesteelbloed werd bepaald door Ju-
rien de koning (Academisch Ziekenhuis Leiden). Dank 
gaat verder uit naar Piet Uytterlinden en Theo Ver-
leun en alle anderen van het Lab. D4 voor hun PRL be-
palingen en steun bij de proefdieren. De gegevens 
werden statistisch bewerkt met de bereidwillige hulp 
van Peter Schenck. 
Veel waardering wil ik uitspreken voor Jan Birken-
hager die, alhoewel slechts zijdelings betrokken bij 
het dierexperimentele onderzoek, te allen tijde op 
inspirerende wijze grate interesse voor het onderzoek 
toonde en vele uren besteedde aan de uiteindelijke 
vorm en inhoud van het proefschrift. Ook Koos van 
der Werff ten Bosch ben ik dank verschuldigd voor de 
gastvrijheid op zijn afdeling en voor de mogelijkheid 
bet onderzoek aldaar te kunnen verrichten. Tevens 
ben ik erkentelijk voor zijn kritische kanttekeningen 
bij de totstandkoming van de manuscripten. 
Het typewerk werd verzorgd door Anneke Bot, Anke de 
Graaff en Corrie Boot-Timmer, die het merendeel van 
de tekst verwerkten op de afdeling ASV. De steun van 
Henk van Beek was hierbij onontbeerlijk. De figuren 
werden op uitstekende wijze door bet audiovisueel 
centrum verzorgd. Tenslotte wil ik allen en met name 
mijn ouders, die niet direct bij het onderzoek be-
trokken zijn geweest dank zeggen voor hun voortdu-
rende morele steun. 
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CURRICULUM VITAE 
De schrijver van di t proefschrift werd op 28 mei I 946 
te Rotterdam geboren. Ih 1964 behaalde hij het di-
ploma HBS-B aan het Charloise Lyceum te Rotterdam. 
Op 12 februari 1971 legde hij het artsexamen aan de 
Rijks Universiteit te Leiden af. Van 1971 tot 1973 
vervulde hij zijn militaire dienstplicht bij de Ko-
ninklijke Marine~ In deze periode was hij 16 maanden 
werkzaam op de interne a£deling van het Marine Hospi-
taal te Overveen (A~D.J. Verburg). Na gedurende 9 
maanden in opleiding te zijn geweest op de kinderaf-
deling van het Elisabeth Ziekenhuis te Tilburg (Dr. 
D.J. van Zaane) werd in october 1973 een aanvang ge-
maakt met de opleiding tot internist (Opleider: 
Dr. P.S. Blom) . In 1978 volgde inschrijving in het 
.specialistenregister. Sindsdien is hij >.verkzaam op 
de afdeling Inwendige Geneeskunde III van het Acade-
misch Ziekenhuis te Rotterdam (Hoofd: Prof. Dr. 
J.C. Birkenhager). 
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